Hereditary Spastic Paraplegia 44

Mendelian MONDO:0013179 Pathograph 16 Show in embeddings browser Hereditary Spastic Paraplegia

SPG44 is an autosomal recessive complex hereditary spastic paraplegia caused by biallelic hypomorphic missense variants in GJC2, the gene encoding connexin-47 (Cx47), the gap-junction protein that couples oligodendrocytes to each other and to astrocytes. It was delineated in a single Italian family carrying homozygous p.I33M and has since been reported in a second, Iranian family. What makes this entry worth curating separately from Pelizaeus-Merzbacher-like disease 1 (PMLD1), the severe infantile hypomyelinating leukodystrophy caused by the same gene, is that the two are not simply "more" and "less" of one lesion. The molecular difference has been measured. PMLD1 alleles such as p.P87S are retained in the endoplasmic reticulum and, in primary oligodendrocytes, activate the unfolded protein response and apoptotic pathways - a toxic gain of function on top of the channel loss. The SPG44 allele p.I33M does neither: it traffics normally, forms gap junction plaques at cell borders like wild-type Cx47, and shows no UPR or apoptotic activation. What it does lose is channel function - it fails to form functional homotypic channels, and the heterotypic I33M/Cx43 channels it does form open only under a large transjunctional voltage difference that is unlikely to occur physiologically. So the mechanism curated here is a comparatively clean loss of panglial coupling without the proteotoxic arm, and the clinical result is correspondingly milder: late onset, slowly progressive complicated spastic paraplegia with normal or near-normal psychomotor development, walking preserved into adulthood, and - diagnostically important - no nystagmus, which is a cardinal PMLD1 sign. The genotype-phenotype relationship is nevertheless not clean, and the entry says so rather than tidying it. In the second reported family a single homozygous GJC2 variant produced a complicated HSP in the proband and a full HLD2 phenotype in both of his sisters. One genotype, two diagnoses, one sibship. Any account of SPG44 as "the mild GJC2 allele class" has to survive that observation, and at present nothing explains it.

Ask OpenScientist

Ask a research question about Hereditary Spastic Paraplegia 44. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

1
Inheritance
4
Pathophys.
4
Phenotypes
2
Gaps
16
Pathograph
1
Genes
2
Variants
3
Medical Actions
3
Models
1
Deep Research
👪

Inheritance

1
Autosomal recessive HP:0000007
Homozygous GJC2 missense variants in consanguineous or geographically isolated families. Heterozygous carriers are unaffected in both published families.
Autosomal recessive inheritance
Show evidence (2 references)
PMID:19056803 SUPPORT Human Clinical
"Here we describe three patients from one family with a novel recessively inherited mutation, 99C>G (predicted to cause an Ile>Met amino acid substitution; I33M) that causes a milder phenotype."
States the recessive inheritance and the founding allele in the index family.
PMID:37915394 SUPPORT Human Clinical
"A novel homozygous variant, c.G14T:p.Ser5Ile, in the GJC2 gene was identified. The variant was co-segregated with the disease status in the family members."
Independent family with homozygosity and formal co-segregation.
?

Discussions and Knowledge Gaps

2
One homozygous GJC2 variant produced complicated hereditary spastic paraplegia in a proband and full hypomyelinating leukodystrophy 2 in both of his sisters. If allele class does not determine which GJC2 disease a patient gets, what does?
OPEN QUESTION OPEN spg44_same_genotype_two_diagnoses
Attached to
genetic#GJC2 pathophysiology#Connexin-47 Channel Loss of Function disease#Hereditary Spastic Paraplegia 44
The tidy account of GJC2 disease is a severity ladder set by allele class: ER-retained, UPR-activating alleles give infantile PMLD1/HLD2; a trafficking-competent but channel-dead allele gives late-onset SPG44. The functional work supports that ladder well - p.I33M shows wild-type-like distribution and no UPR or apoptotic activation, where p.P87S, p.Y269D and p.M283T show ER retention and both. The second SPG44 family breaks it. All three affected siblings are homozygous for the same novel c.14G>T (p.S5I) variant, and the proband has complicated HSP while both sisters have HLD2. Within one sibship, one genotype, two diagnoses. Their own authors read this as evidence for a shared pathophysiology across the GJC2 spectrum rather than as a challenge to the ladder, and both readings are available from the same observation. This is filed as an OPEN_QUESTION rather than a KNOWLEDGE_GAP because the relevant measurement has not merely been omitted - it is not clear what the measurement would be. Modifier alleles, differences in the astrocytic connexin partners, and stochastic developmental factors are all live candidates, and no source cited here distinguishes them. A practical consequence follows, and it is recorded in the counselling treatment entry: a recurrence in a family with a known "mild" GJC2 allele cannot be counselled as mild.
Show evidence (3 references)
PMID:37915394 SUPPORT Human Clinical
"Clinical evaluation of all patients showed two distinct GJC2-related phenotypes in this family; the proband presented a complicated form of HSP, whereas both his affected sisters presented a HLD2 phenotype."
The discordance this discussion is about, within one sibship and one genotype.
PMID:37915394 SUPPORT Human Clinical
"Such intrafamilial phenotypic heterogeneity for GJC2 can emphasize on the shared pathophysiology of these disorders."
The authors' own reading of the same fact, recorded because this entry does not adjudicate between it and the allele-ladder reading.
PMID:35276347 SUPPORT In Vitro
"three PMLD1 associated mutants (p.P87S, p.Y269D and p.M283T) show ER retention of Cx47 and evidence of activation of the cellular stress (unfolded protein response, UPR) and apoptotic pathways"
The allele-class ladder that the intrafamilial discordance has to be reconciled with.
Cx47-null mice have vacuolated myelin but no overt phenotype, while humans homozygous for a channel-dead GJC2 allele develop progressive spastic paraplegia. Is the difference mouse connexin redundancy, or does the human allele do something a null does not?
HUMAN MODEL MISMATCH OPEN spg44_single_connexin_mouse_redundancy
Attached to
animal_models#Cx47-null mouse (Gjc2 single knockout) pathophysiology#Disrupted Oligodendrocyte-Astrocyte Panglial Coupling pathophysiology#Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
Evidence exists in the model; what is uncertain is whether it transfers. Established in mouse: deleting Cx47 alone leaves animals fertile and behaviourally normal with a purely ultrastructural myelin lesion. Deleting Cx47 together with the second oligodendrocytic connexin Cx32 gives action tremor and death at around 51 days. Deleting it together with the astrocytic Cx30 abolishes oligodendrocyte-to-astrocyte coupling, causes severe vacuolation in all white-matter tracts, and kills about 40% of animals within 42-90 days. The mouse therefore needs two connexins removed to become ill. Established in human: two families homozygous for GJC2 missense alleles develop hypomyelinating leukoencephalopathy with progressive spastic paraplegia, from a single connexin lesion. Two readings are open and this entry does not choose. Either mouse oligodendrocytes are protected by a Cx32 redundancy that human oligodendrocytes do not have to the same degree - in which case the single-knockout null result says nothing about the human disease - or the human missense alleles are not simple nulls and exert an effect a null cannot. The second reading is specifically not excluded for SPG44 by the UPR work, which ruled out the ER-retention and apoptosis arm but not every possible non-channel function: the founding report ends by saying it is not known whether I33M retains a Cx47 function unrelated to forming functional channels. Filed as HUMAN_MODEL_MISMATCH rather than KNOWLEDGE_GAP because the model data exist and are good; the open question is their translational validity.
Proposed experiments
Knock-in of the human SPG44 allele versus Cx47 null, on a matched background
exp_spg44_knockin_vs_null_mouse
Generate a Gjc2 p.I33M knock-in mouse and compare it directly with the existing Cx47 null for oligodendrocyte-astrocyte biocytin coupling, myelin ultrastructure, and motor behaviour. A knock-in that is worse than the null would show the human allele is not a simple loss of function; a knock-in indistinguishable from the null would leave species redundancy as the explanation for the mouse-human gap.
Would support
pathophysiology#Connexin-47 Channel Loss of Function
Supporting outcome
  • The p.I33M knock-in phenocopies the null, with coupling loss and subclinical myelin vacuolation only, supporting a pure loss-of-conductance mechanism whose mildness in mouse reflects Cx32 redundancy.
Refuting outcome
  • The p.I33M knock-in is more severely affected than the null, indicating the missense protein exerts an effect beyond loss of channel function and that the mechanism curated here is incomplete.
Show evidence (3 references)
PMID:12805295 SUPPORT Model Organism
"Homozygous mutant mice were fertile and showed no obvious morphological or behavioral abnormalities."
The mismatch itself - a single-connexin null mouse with no disease.
PMID:22649229 SUPPORT Model Organism
"probably caused by the upregulation of oligodendrocytic Cx32 in Cx30/Cx47 double-deficient mice"
Names the compensating connexin explicitly, which is what makes the redundancy reading concrete rather than a general appeal to species difference.
PMID:19056803 SUPPORT In Vitro
"whether I33M retains a function of Cx47 not directly related to forming functional gap junction channels is not known"
The authors' explicit statement that the non-channel-function reading is open, which is why this discussion does not settle on redundancy alone.
⚙

Pathophysiology

4
Connexin-47 Channel Loss of Function
Biallelic hypomorphic GJC2 missense variants leave connexin-47 protein present and correctly delivered but unable to conduct. In transfected cells the p.I33M protein forms gap junction plaques at cell borders indistinguishable from wild-type Cx47, yet fails to form functional homotypic channels in both scrape-loading and dual whole-cell patch-clamp assays. This is the node that separates SPG44 from PMLD1 and it is worth being precise about why. The severe PMLD1 alleles are ER-retained and, in primary oligodendrocytes, switch on the unfolded protein response and apoptosis - loss of channel plus a proteotoxic gain of function. The SPG44 allele shows wild-type-like distribution and no UPR or apoptotic activation. The lesion here is confined to conductance.
GJC2 hgnc:17494 HUGO Gene Nomenclature Committee (hgnc) Relation: this pathophysiological event involves this gene This pathophysiological event involves GJC2 (hgnc:17494). hgnc:17494 is a gene from the HUGO Gene Nomenclature Committee.
Genetic context allele_type: VARIANT variant_origin: GERMLINE zygosity: HOMOZYGOUS functional_impact_category: LOSS_OF_FUNCTION
connexin-47 gap junction channel activity GO:0005243 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves connexin-47 gap junction channel activity, annotated with gap junction channel activity (GO:0005243), qualified as loss of function. GO:0005243 is a molecular function from the Gene Ontology. ⇓ LOSS OF FUNCTION
gap junction plaque at the oligodendrocyte membrane GO:0005921 Gene Ontology (GO) Relation: this pathophysiological event involves this cellular component This pathophysiological event involves gap junction plaque at the oligodendrocyte membrane, annotated with gap junction (GO:0005921). GO:0005921 is a cellular component from the Gene Ontology.
Downstream
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
Show evidence (2 references)
PMID:19056803 SUPPORT In Vitro
"The mutant protein forms gap junction plaques at cell borders similar to wild-type (WT) Cx47 in transfected cells, but fails to form functional homotypic channels in scrape-loading and dual whole-cell patch clamp assays."
Two orthogonal assays establish that trafficking is preserved while conductance is lost - the precise shape of this node's claim.
PMID:35276347 SUPPORT INDIRECT In Vitro
"the milder SPG44 associated mutation p.I33M shows a wild-type-like subcellular distribution and no activation of the UPR or apoptotic pathways"
Supports confining this node to channel loss of function, by ruling out in primary oligodendrocytes the ER-retention and proteotoxic arm that the PMLD1 alleles show. Recorded as INDIRECT because the result is an exclusion - it establishes what the SPG44 allele does not do, from which the narrower mechanism follows.
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
Cx47 is the oligodendrocyte partner in the panglial network: Cx47/Cx43 channels join oligodendrocytes to astrocytes, and Cx47 also contributes to oligodendrocyte-oligodendrocyte coupling. The SPG44 allele does form overlapping plaques and channels with Cx43, but those channels open only when a large voltage difference is applied across the paired cells - a condition the founding authors judge unlikely to be met physiologically. The functional result is therefore the same disruption of astrocyte-oligodendrocyte coupling that the ER-retained PMLD1 mutants cause, reached by a different molecular route. That this coupling is what matters, rather than Cx47 protein presence, is what the mouse genetics show: removing Cx47 alone leaves the animal essentially well, while removing Cx47 together with the astrocytic or the second oligodendrocytic connexin abolishes oligodendrocyte-to-astrocyte coupling and produces overt myelin disease.
oligodendrocyte CL:0000128 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves oligodendrocyte (CL:0000128). CL:0000128 is a cell type from the Cell Ontology. astrocyte CL:0000127 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves astrocyte (CL:0000127). CL:0000127 is a cell type from the Cell Ontology.
heterotypic Cx47/Cx43 gap junction channel activity GO:0005243 Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves decreased heterotypic Cx47/Cx43 gap junction channel activity, annotated with gap junction channel activity (GO:0005243). GO:0005243 is a molecular function from the Gene Ontology. ↓ DECREASED
Animal models
Cx47-null mouse (Gjc2 single knockout) Mouse measures The EGFP reporter knock-in localised Cx47 expression to oligodendrocytes in highly myelinated CNS tissue, which is what licenses treating an oligodendrocyte gap-junction defect as the cell of origin in the human disease.
Cx32/Cx47 double-null mouse Mouse rescues The same model is the platform on which restoring gap-junctional coupling has been shown to correct the disease - twice, by two different routes. Transgenic oligodendrocytic expression of human Cx32 rescued the severe demyelinating phenotype and prevented early mortality; an AAV vector delivering Cx47 under the myelin basic protein promoter, injected once at postnatal day 10, improved motor performance and survival and re-established dye transfer between oligodendrocytes.
Cx30/Cx47 double-null mouse Mouse recapitulates Oligodendrocyte-to-astrocyte coupling is completely disrupted while oligodendrocyte-to-oligodendrocyte coupling is maintained - the precise selectivity this node asserts for the human allele.
Downstream
CNS Hypomyelination and Myelin Instability
Show evidence (2 references)
PMID:19056803 SUPPORT In Vitro
"These channels probably do not function under physiological conditions, suggesting that Cx47/Cx43 channels between astrocytes and oligodendrocytes are disrupted, similar to the loss-of-function endoplasmic reticulum-retained Cx47 mutants that cause PMLD."
The authors' own inference from the electrophysiology, with their hedges ("probably", "suggesting") kept inside the quote because they carry the strength of the claim.
PMID:22649229 SUPPORT INDIRECT Model Organism
"Biocytin injections revealed complete disruption of oligodendrocyte-to-astrocyte coupling in the white matter of 10- to 15-d-old Cx30/Cx47 double-deficient mice, while oligodendrocyte-to-oligodendrocyte coupling was maintained."
Demonstrates directly that losing Cx47 in combination severs the oligodendrocyte-astrocyte arm specifically. INDIRECT because the mouse genotype is a double knockout, not the human hypomorphic missense state.
CNS Hypomyelination and Myelin Instability
Loss of panglial coupling leaves the CNS myelin sheath deficient. In the SPG44 family, brain MRI and MR spectroscopy were consistent with a hypomyelinating leukoencephalopathy - the same imaging class as PMLD1, at lower severity. In mice, the corresponding lesion is vacuolation of myelinated fibres, most conspicuous in the optic nerve where oligodendrocytes first contact axons, and it worsens sharply when a second connexin is removed.
central nervous system myelination GO:0022010 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased central nervous system myelination (GO:0022010). GO:0022010 is a biological process from the Gene Ontology. ↓ DECREASED
Animal models
Cx47-null mouse (Gjc2 single knockout) Mouse partially recapitulates Reproduces the myelin lesion at the ultrastructural level - conspicuous vacuolation of nerve fibres in CNS white matter, maximal in the optic nerve.
Cx32/Cx47 double-null mouse Mouse recapitulates Action tremor with death at a mean of 51 days and much more abundant white-matter vacuolation than the single knockout.
Cx30/Cx47 double-null mouse Mouse recapitulates Severe vacuolation and myelination defects in all CNS white-matter tracts, with reduced oligodendrocyte numbers, astrogliosis and microglial activation, plus motor impairment and early death in about 40% of animals.
Downstream
Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
CNS Hypomyelination on MRI The imaging phenotype is the direct radiological readout of this node, not a separate consequence of it.
Ataxia Hypomyelination is not confined to the corticospinal tracts, and the late-onset GJC2 patients who show prominent ataxia show it alongside the same distinctive hypomyelinating MRI pattern. The intermediates between diffuse hypomyelination and a cerebellar syndrome are not established, which is why this link is INDIRECT_UNKNOWN_INTERMEDIATES rather than DIRECT.
Parkinsonism Reported in one sibling of the late-onset Turkish family, alongside the same MRI pattern. A single individual, so the link is drawn but weakly.
Show evidence (2 references)
PMID:19056803 SUPPORT Human Clinical
"MRI and MR spectroscopy imaging were consistent with a hypomyelinating leukoencephalopathy."
The human tissue-level finding, from imaging in the index family.
PMID:12805295 SUPPORT Model Organism
"Electron microscopic analysis of CNS white matter in Cx47-deficient mice revealed a conspicuous vacuolation of nerve fibers, particularly at the site of the optic nerve where axons are first contacted by oligodendrocytes and myelination starts."
Ultrastructural myelin pathology attributable to Cx47 loss alone, in the compartment this node names.
Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
The clinical endpoint. Deficient myelination of long descending motor tracts produces a late-onset, slowly progressive complicated spastic paraplegia. What distinguishes it from the PMLD1 course is what is preserved: psychomotor development is normal or near-normal, walking is retained through adulthood, and nystagmus - a cardinal PMLD1 sign - is absent.
Animal models
Cx47-null mouse (Gjc2 single knockout) Mouse fails to recapitulate Cx47-null mice are fertile and show no obvious morphological or behavioural abnormality. The single knockout does not produce the human motor disease.
Downstream
Progressive Spastic Paraplegia
Show evidence (1 reference)
PMID:19056803 SUPPORT Human Clinical
"All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus."
The complete clinical description of the founding family, including the three preserved features that separate SPG44 from PMLD1 at the bedside.
⬡

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Hereditary Spastic Paraplegia 44 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

4
Musculoskeletal 1
Progressive Spastic Paraplegia VERY_FREQUENT HP:0001258 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spastic paraplegia (HP:0001258), qualified as course progressive; adult onset. HP:0001258 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE Onset: ADULT
Show evidence (2 references)
PMID:19056803 SUPPORT Human Clinical
"All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus."
Direct statement of the phenotype, its onset and its course in all three affected individuals.
PMID:37915394 SUPPORT Human Clinical
"the proband presented a complicated form of HSP, whereas both his affected sisters presented a HLD2 phenotype"
The second family's proband, and simultaneously the observation that the same genotype produced HLD2 in his sisters.
Nervous System 2
Ataxia OCCASIONAL HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:31431325 SUPPORT Human Clinical
"Our findings confirm and further expand the late-onset phenotypes of GJC2 mutations, to include prominent ataxia, pyramidal disturbances and mild parkinsonism, and confirm the distinctive associated MRI pattern."
Ataxia in the late-onset GJC2 spectrum. Frequency is OCCASIONAL rather than higher because the founding SPG44 family is not described as ataxic and this comes from a separate family reported under a different label.
Parkinsonism VERY_RARE HP:0001300 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Parkinsonism (HP:0001300), qualified as severity mild. HP:0001300 is a phenotype from the Human Phenotype Ontology.
Severity: MILD
Show evidence (1 reference)
PMID:31431325 SUPPORT Human Clinical
"Our findings confirm and further expand the late-onset phenotypes of GJC2 mutations, to include prominent ataxia, pyramidal disturbances and mild parkinsonism, and confirm the distinctive associated MRI pattern."
The same sentence that carries the ataxia claim. There are too few published patients for any numeric frequency band to be read literally - the whole late-onset GJC2 literature is single digits - so no percentage is claimed here. VERY_RARE records that parkinsonism is a singular, non-core observation: one individual, in one family, reported under the late-onset GJC2 label rather than as SPG44. The sibling asymmetry - the abstract's OBJECTIVE section attributes parkinsonism to one of the two siblings where ataxia and pyramidal disturbances are attributed to both - is why it is not banded alongside ataxia, and is not itself the frequency.
Other 1
CNS Hypomyelination on MRI VERY_FREQUENT HP:0003429 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is CNS hypomyelination (HP:0003429). HP:0003429 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:19056803 SUPPORT Human Clinical
"MRI and MR spectroscopy imaging were consistent with a hypomyelinating leukoencephalopathy."
The imaging finding in the founding family.
PMID:37915394 SUPPORT Human Clinical
"the screening of GJC2 in patients with HSP or HSP-like phenotypes especially with hypomyelination in their brain MRI is recommended"
Ties the imaging phenotype to a testing recommendation, which is the practical reason to record it separately from the motor phenotype.
🧬

Genetic Associations

1
GJC2
Gene: GJC2 hgnc:17494 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is GJC2 (hgnc:17494). hgnc:17494 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE
Show evidence (1 reference)
PMID:19056803 SUPPORT Human Clinical
"Thus, GJA12/GJC2 mutations can result in a milder phenotype than previously appreciated"
The authors' own summary of the gene-disease relationship. Deliberately cut at the comma: the rest of that sentence is an in-vitro statement about what the I33M protein may still do, which is a different claim with a different evidence source, and it is quoted separately in the model-mismatch discussion.
Variants (2)
c.99C>G (p.I33M)
Homozygous missense variant in the founding Italian family. Traffics and forms plaques like wild-type Cx47 but is channel-dead as a homotypic channel; heterotypic I33M/Cx43 channels open only at large transjunctional voltages.
Show evidence (1 reference)
PMID:19056803 SUPPORT In Vitro
"I33M forms overlapping gap junction plaques and functional channels with Cx43, however, I33M/Cx43 channels open only when a large voltage difference is applied to paired cells."
The electrophysiological characterisation of the founding allele.
c.14G>T (p.S5I)
Novel homozygous missense variant in the second, Iranian family, co-segregating with disease. The proband had complicated HSP; two sisters homozygous for the same variant had HLD2.
Show evidence (1 reference)
PMID:37915394 SUPPORT Human Clinical
"A novel homozygous variant, c.G14T:p.Ser5Ile, in the GJC2 gene was identified. The variant was co-segregated with the disease status in the family members."
Identifies the second family's allele and its co-segregation.
💊

Medical Actions

3
Genetic Counseling
Action: Genetic CounselingNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Genetic Counseling (NCIT:C15240). NCIT:C15240 is a clinical intervention from the NCI Thesaurus. NCIT:C15240
Both published families are homozygous for private missense variants, so recurrence-risk counselling and carrier testing are directly indicated. The second family gives counselling an unusually concrete content: siblings homozygous for the same variant had markedly different phenotypes, so a recurrence cannot be predicted to be mild.
Show evidence (1 reference)
PMID:37915394 SUPPORT Human Clinical
"Clinical evaluation of all patients showed two distinct GJC2-related phenotypes in this family; the proband presented a complicated form of HSP, whereas both his affected sisters presented a HLD2 phenotype."
The intrafamilial discordance that makes prognostic counselling on genotype alone unsupportable in this disorder.
Symptomatic Management of Spasticity
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
No disease-modifying therapy exists. Care follows general hereditary spastic paraplegia practice - physiotherapy, mobility support, antispastic measures. Recorded with no specific agent bound, because neither cited source makes a drug recommendation for SPG44.
Mechanism Target:
Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis — Addresses the functional consequence only. Nothing available acts on the coupling defect upstream of it.
Show evidence (1 reference)
PMID:19056803 SUPPORT INDIRECT Human Clinical
"preserved walking capability through adulthood"
Establishes the ambulatory status that supportive care is aimed at maintaining. INDIRECT because no cited source states a management recommendation for this disorder; the claim that supportive care is what is available follows from the absence of anything else, not from this sentence.
Oligodendrocyte-Targeted AAV-GJC2 Gene Therapy (preclinical only)
Action: Gene TherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Gene Therapy (NCIT:C15238). NCIT:C15238 is a clinical intervention from the NCI Thesaurus. NCIT:C15238
NOT A TREATMENT FOR PATIENTS. A single intracerebral injection of AAV.MBP.Cx47myc - the GJC2 coding sequence under the myelin basic protein promoter, so expression is restricted to oligodendrocytes - at postnatal day 10 improved motor performance and coordination and prolonged survival in Cx32/Cx47 double-knockout mice, with improvement in demyelination, oligodendrocyte apoptosis, inflammation and astrogliosis, and re-established gap-junctional dye transfer between oligodendrocytes. The mechanistic rationale is unusually direct for SPG44 in particular. The disease node this acts on is loss of channel function, and the SPG44 allele has been shown not to carry the ER-retention and proteotoxic arm that the severe alleles do - so there is no misfolded species to clear before a replacement connexin can work. A replacement strategy is matched to a clean loss of function in a way it would not be to a toxic gain of function. Two things keep this firmly preclinical. No human has been treated and no trial exists. And the model treated is the Cx32/Cx47 double knockout, which corresponds to severe PMLD1, not to the mild SPG44 course - so the rescue is demonstrated against a disease severity that SPG44 patients do not have.
Mechanism Target:
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling — Restores oligodendrocyte gap-junctional connectivity directly, which is the node one step below the genetic lesion. Dye transfer between oligodendrocytes was re-established in treated animals, so the intended molecular effect was measured rather than assumed.
Show evidence (2 references)
PMID:28100454 SUPPORT Model Organism
"Application of this oligodendrocyte-targeted somatic gene therapy at postnatal Day 10 in groups of double knockout mice, a well characterized model of hypomyelinating leukodystrophy-2, resulted in significant improvement in motor performance and coordination at 1 month of age in treated compared..."
The preclinical rescue result, in mouse, with the treatment age stated. Graded MODEL_ORGANISM because it is entirely a mouse result and the entry does not represent it as anything else.
PMID:25524707 SUPPORT Model Organism
"Our study confirms that loss of oligodendrocyte GJs has cell autonomous effects and that re-establishment of GJ connectivity by replacement of least one GJ protein provides correction of the leukodystrophy phenotype."
The genetic proof of principle that preceded the vector work, and the reason to think the target is correct: restoring gap-junctional connectivity by any oligodendrocytic connexin corrects the phenotype, so the defect is the coupling rather than Cx47 itself.
🔬

Diagnosis

2
GJC2 Sequencing Prompted by Hypomyelinating MRI
The productive diagnostic route is an HSP or HSP-like presentation whose brain MRI shows hypomyelination, followed by GJC2 sequencing. This is the recommendation the second family's authors make explicitly, and it matters because a patient labelled HSP will not usually have a leukodystrophy gene tested.
Show evidence (2 references)
PMID:37915394 SUPPORT Human Clinical
"the screening of GJC2 in patients with HSP or HSP-like phenotypes especially with hypomyelination in their brain MRI is recommended"
The authors' explicit testing recommendation.
PMID:31431325 SUPPORT Human Clinical
"Brain MRI showed hyperintense signal in T2-weighted images in the internal capsule and subcortical and periventricular white matter, consistent with hypomyelination."
Describes the imaging pattern concretely, in an independent late-onset GJC2 family, which is what makes the MRI-first strategy actionable.
Brainstem Auditory Evoked Potentials to Separate GJC2 from PLP1 Disease
GJC2 disease and PLP1-related Pelizaeus-Merzbacher disease are described as almost indistinguishable clinically and radiologically, and both can present as a hypomyelinating leukoencephalopathy with spasticity. Brainstem auditory evoked potentials separate them: waves III-V were absent in every PLP1 patient studied and clearly recordable in most GJC2 patients. In a patient whose pedigree is compatible with either, this is a cheap test that points at the right gene first. The same series found nerve conduction studies normal in all PLP1 patients and indicating mild peripheral neuropathy in 2 of 10 GJC2 patients - worth knowing when interpreting a mildly abnormal NCS, though those patients carried the severe PMLD alleles rather than the SPG44 ones and no peripheral neuropathy is reported in either published SPG44 family.
Show evidence (2 references)
PMID:20513814 SUPPORT INDIRECT Human Clinical
"In brainstem auditory EP, waves III-V were absent in all patients with PMD, but clearly recordable in 11 of 13 investigations in 8 patients with PMLD."
The discriminating result. INDIRECT for SPG44 because the GJC2 patients studied had PMLD rather than SPG44; the inference is that a test separating GJC2 from PLP1 disease does so by the gene, not by the severity, and the entry says so rather than implying the study included SPG44 patients.
PMID:20513814 SUPPORT INDIRECT Human Clinical
"NCS were normal in all patients with PMD and indicated mild peripheral neuropathy in only 2 of 10 patients with PMLD."
The peripheral-nerve finding, at the frequency the study reports. INDIRECT for the same reason: these are PMLD patients, and no SPG44 patient has been reported with neuropathy.
📈

Progression

2
Onset
Age: late onset, after normal or near-normal psychomotor development
Unlike PMLD1, which presents in infancy with nystagmus and psychomotor delay, SPG44 begins after development has proceeded normally or near-normally. The onset difference is as much a discriminator as the severity difference.
Show evidence (1 reference)
PMID:19056803 SUPPORT Human Clinical
"All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus."
States the late onset and the preserved early development.
Established disease
Slowly progressive, with walking capability preserved through adulthood in all three individuals of the founding family. No published SPG44 patient has lost ambulation, but with two families and no longitudinal cohort this is an absence of reported progression rather than a demonstrated plateau.
Show evidence (1 reference)
PMID:19056803 SUPPORT Human Clinical
"slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood"
The course and the functional outcome, as far as the founding report records them.
📊

Prevalence

1
Worldwide (published cases)
Cases In Literature Ultra Rare
Two families in total. Three affected individuals in the founding Italian family, and one proband in the second, Iranian family - whose own authors state that the HSP-GJC2 correlation had been reported only once before them. No population prevalence estimate for SPG44 has been published, and none is asserted here.
Show evidence (1 reference)
PMID:37915394 SUPPORT Human Clinical
"Up to now, correlation between HSP and GJC2 variants has been reported once. Here, the second case of SPG44 was identified that emphasizes on GJC2 as a HSP-causing gene."
Establishes the published-case count directly: one prior report, this being the second.
🐁

Animal Models

3
Cx47-null mouse (Gjc2 single knockout)
Germline replacement of the Cx47 coding sequence with EGFP under the endogenous promoter. The reporter also settled where Cx47 is expressed - predominantly oligodendrocytes in highly myelinated CNS tissue, correcting an earlier claim of neuronal expression.
Species
Mouse
Genotype
Cx47-null (Gjc2 coding DNA replaced by EGFP reporter)
Publication
PMID:12805295
Pathograph links
CNS Hypomyelination and Myelin Instability partially recapitulates fidelity: moderate Reproduces the myelin lesion at the ultrastructural level - conspicuous vacuolation of nerve fibres in CNS white matter, maximal in the optic nerve.
Limitations: The lesion is subclinical. It is visible by electron microscopy in an animal with no overt phenotype, so the model captures the myelin abnormality without the disease.
Readouts
Myelinated fibre vacuolation on electron microscopy
Direction: INCREASED
Interpretation: Ultrastructural correlate of the myelin node, attributable to Cx47 loss alone.
Show evidence (1 reference)
PMID:12805295 SUPPORT Model Organism
"Electron microscopic analysis of CNS white matter in Cx47-deficient mice revealed a conspicuous vacuolation of nerve fibers, particularly at the site of the optic nerve where axons are first contacted by oligodendrocytes and myelination starts."
Reports the histological measurement behind this readout.
Show evidence (1 reference)
PMID:12805295 SUPPORT Model Organism
"Cx47 protein was detected by Western blot analysis after immunoprecipitation in CNS tissues of wild-type mice but not in heart or Cx47-deficient tissues."
Supports treating this model as informative for the myelin node by establishing that it is a genuine protein null rather than a knockdown, which is the precondition for reading its myelin lesion as a Cx47 loss-of-function phenotype.
Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis fails to recapitulate fidelity: low Cx47-null mice are fertile and show no obvious morphological or behavioural abnormality. The single knockout does not produce the human motor disease.
Limitations: This is a species-level difference in connexin redundancy, not a technical failure of the model. Mouse oligodendrocytes retain Cx32 and mouse astrocytes retain Cx30 and Cx43, and removing a second connexin alongside Cx47 does produce overt disease - action tremor and death by around 51 days in Cx32/Cx47 double nulls. Any inference from a single-connexin mouse to a human GJC2 patient therefore has to account for a redundancy the human does not obviously share, and this entry does not use the single knockout as evidence for or against the human motor phenotype.
Readouts
Overt morphological and behavioural phenotype
Direction: UNCHANGED
Interpretation: No detectable phenotype in the single knockout - a real negative result, and the reason the fidelity here is LOW.
Show evidence (1 reference)
PMID:12805295 REFUTE Model Organism
"Homozygous mutant mice were fertile and showed no obvious morphological or behavioral abnormalities."
Refutes the proposition that Cx47 loss alone reproduces the human motor phenotype in the mouse.
Show evidence (1 reference)
PMID:12805295 REFUTE Model Organism
"Homozygous mutant mice were fertile and showed no obvious morphological or behavioral abnormalities."
The substantiating negative result required for a FAILS_TO_RECAPITULATE link: the model is not informative for the clinical motor node.
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling measures fidelity: moderate The EGFP reporter knock-in localised Cx47 expression to oligodendrocytes in highly myelinated CNS tissue, which is what licenses treating an oligodendrocyte gap-junction defect as the cell of origin in the human disease.
Limitations: An expression measurement, not a disease measurement. It establishes where the protein is, not what its loss does.
Readouts
Cell-type localisation of Cx47 expression by EGFP reporter
Interpretation: Places Cx47 in oligodendrocytes rather than neurons. `direction` is deliberately omitted: the measurement was made, but it is a localisation rather than an increase or decrease, and ModelReadoutDirectionEnum has no value for a non-directional result.
Show evidence (1 reference)
PMID:12805295 SUPPORT Model Organism
"Cx47 was mainly expressed in oligodendrocytes in highly myelinated CNS tissues and in few calcium-binding protein S100beta subunit-positive cells but not in neurons or peripheral sciatic nerve."
Reports the expression measurement behind this readout.
Show evidence (1 reference)
PMID:12805295 SUPPORT Model Organism
"This corrects our previous conclusion that Cx47 mRNA is expressed in brain and spinal cord neurons (Teubner et al., 2001)."
Worth quoting for provenance: the same group is retracting its own earlier localisation, which is why this measurement rather than the older one should be relied on.
Cx32/Cx47 double-null mouse
Removing the second oligodendrocytic connexin alongside Cx47 converts the subclinical single-knockout lesion into overt, lethal white-matter disease.
Species
Mouse
Genotype
Gjb1-null; Gjc2-null (Cx32/Cx47 double-deficient)
Publication
PMID:12805295
Pathograph links
CNS Hypomyelination and Myelin Instability recapitulates fidelity: moderate Action tremor with death at a mean of 51 days and much more abundant white-matter vacuolation than the single knockout.
Limitations: Two genes are removed, and the human disease involves one. The model demonstrates that oligodendrocytic gap-junctional coupling is what matters, but its severity and lethality are not the SPG44 course, which is late-onset and compatible with adult ambulation.
Readouts
White-matter fibre vacuolation relative to single knockout
Direction: INCREASED
Interpretation: Dose-dependence of the myelin lesion on total oligodendrocytic connexin loss.
Show evidence (1 reference)
PMID:12805295 SUPPORT Model Organism
"The central white matter of these double-deficient mice exhibited much more abundant vacuolation in nerve fibers than mice deficient only in Cx47."
Reports the comparative histological measurement behind this readout.
Show evidence (1 reference)
PMID:12805295 SUPPORT Model Organism
"Initial analyses of Cx32/Cx47-double-deficient mice showed that these mice developed an action tremor and died on average at 51 d after birth."
Supports treating this model as informative for the myelin node, with an overt phenotype.
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling rescues fidelity: moderate The same model is the platform on which restoring gap-junctional coupling has been shown to correct the disease - twice, by two different routes. Transgenic oligodendrocytic expression of human Cx32 rescued the severe demyelinating phenotype and prevented early mortality; an AAV vector delivering Cx47 under the myelin basic protein promoter, injected once at postnatal day 10, improved motor performance and survival and re-established dye transfer between oligodendrocytes.
Limitations: Both rescues are in the double knockout, which is a model of severe PMLD1 rather than of SPG44, and both intervene at postnatal day 10 or earlier - before the human disease would be diagnosed. What they establish for SPG44 is that the coupling defect is correctable in principle and that the target is the coupling rather than Cx47 protein identity; they do not establish a therapeutic window for a late-onset human disease.
Readouts
Oligodendrocyte gap-junctional dye transfer after AAV-Cx47
Direction: RESTORED
Interpretation: Direct confirmation that the intended molecular effect was achieved, not just a behavioural improvement.
Show evidence (1 reference)
PMID:28100454 SUPPORT Model Organism
"Functional dye transfer analysis confirmed the re-establishment of oligodendrocyte gap junctional connectivity in treated as opposed to untreated mice."
Reports the coupling measurement behind this readout.
Survival and motor performance after transgenic Cx32 replacement
Direction: RESTORED
Interpretation: Genetic rather than vector-delivered rescue, and by a different connexin - which is what makes the target the coupling rather than Cx47 specifically.
Show evidence (1 reference)
PMID:25524707 SUPPORT Model Organism
"transgenic expression of hCx32 rescued the severe early phenotype of CNS demyelination in Cx32/Cx47dKO mice, resulting in marked improvement of behavioral abnormalities at 1 month of age, and preventing the early mortality"
Reports the survival and behavioural rescue behind this readout.
Show evidence (1 reference)
PMID:25524707 SUPPORT Model Organism
"Our study confirms that loss of oligodendrocyte GJs has cell autonomous effects and that re-establishment of GJ connectivity by replacement of least one GJ protein provides correction of the leukodystrophy phenotype."
Supports treating this model as informative for the coupling node in the rescue direction, and states the cell-autonomy conclusion that the gene-therapy strategy rests on.
Cx30/Cx47 double-null mouse
Removes the astrocytic partner connexin instead of the second oligodendrocytic one, and so isolates the oligodendrocyte-to-astrocyte arm of panglial coupling specifically. This is the closest experimental analogue of the coupling defect inferred in SPG44.
Species
Mouse
Genotype
Gjb6-null; Gjc2-null (Cx30/Cx47 double-deficient)
Publication
PMID:22649229
Pathograph links
Disrupted Oligodendrocyte-Astrocyte Panglial Coupling recapitulates fidelity: moderate Oligodendrocyte-to-astrocyte coupling is completely disrupted while oligodendrocyte-to-oligodendrocyte coupling is maintained - the precise selectivity this node asserts for the human allele.
Limitations: A double knockout of two connexins, one of them astrocytic, standing in for a human hypomorphic missense allele in the oligodendrocytic connexin alone. The coupling defect is the shared feature; the genetic architecture is not.
Readouts
Oligodendrocyte-to-astrocyte biocytin coupling
Direction: ABOLISHED
Interpretation: Direct measurement of the coupling loss, with the oligodendrocyte-oligodendrocyte arm preserved as an internal control.
Show evidence (1 reference)
PMID:22649229 SUPPORT Model Organism
"Biocytin injections revealed complete disruption of oligodendrocyte-to-astrocyte coupling in the white matter of 10- to 15-d-old Cx30/Cx47 double-deficient mice, while oligodendrocyte-to-oligodendrocyte coupling was maintained."
Reports the dye-coupling measurement behind this readout.
Show evidence (1 reference)
PMID:22649229 SUPPORT Model Organism
"show that both connexins are required for maintenance of myelin"
Supports treating this model as informative for the coupling node.
CNS Hypomyelination and Myelin Instability recapitulates fidelity: moderate Severe vacuolation and myelination defects in all CNS white-matter tracts, with reduced oligodendrocyte numbers, astrogliosis and microglial activation, plus motor impairment and early death in about 40% of animals.
Limitations: Far more severe than SPG44 and closer to PMLD1 in course. Useful as evidence that coupling loss causes myelin failure, not as a model of the SPG44 severity.
Readouts
White-matter vacuolation and myelination defects
Direction: INCREASED
Interpretation: The myelin consequence of severed panglial coupling.
Show evidence (1 reference)
PMID:22649229 SUPPORT Model Organism
"Histological and ultrastructural analyses revealed severe vacuolization and myelination defects in all white matter tracts of the CNS."
Reports the histological measurement behind this readout.
Myelin sheath thickness in surviving adults
Direction: DECREASED
Interpretation: The lesion persists rather than resolving in animals that survive, which is what makes it a maintenance failure rather than a developmental delay.
Show evidence (1 reference)
PMID:22649229 SUPPORT Model Organism
"Vacuole formation and thinner myelin sheaths were evident also with adult surviving double-KO mice."
Reports the adult ultrastructural measurement behind this readout.
Show evidence (1 reference)
PMID:22649229 SUPPORT Model Organism
"We observed early onset myelin pathology, and ∼40% of Cx30/Cx47 double-deficient animals died within 42 to 90 d after birth, accompanied by severe motor impairments."
Supports treating this model as informative for the myelin node.
{ }

Source YAML

click to show 
name: Hereditary Spastic Paraplegia 44
category: Mendelian
creation_date: "2026-08-30T21:10:00Z"
synonyms:
- SPG44
- Spastic paraplegia 44, autosomal recessive
- GJC2-related hereditary spastic paraplegia
- Autosomal recessive complex spastic paraplegia caused by mutation in GJC2
- Connexin-47-related hereditary spastic paraplegia
description: >-
  SPG44 is an autosomal recessive complex hereditary spastic paraplegia caused by biallelic
  hypomorphic missense variants in GJC2, the gene encoding connexin-47 (Cx47), the gap-junction
  protein that couples oligodendrocytes to each other and to astrocytes. It was delineated in a
  single Italian family carrying homozygous p.I33M and has since been reported in a second,
  Iranian family.

  What makes this entry worth curating separately from Pelizaeus-Merzbacher-like disease 1
  (PMLD1), the severe infantile hypomyelinating leukodystrophy caused by the same gene, is that
  the two are not simply "more" and "less" of one lesion. The molecular difference has been
  measured. PMLD1 alleles such as p.P87S are retained in the endoplasmic reticulum and, in
  primary oligodendrocytes, activate the unfolded protein response and apoptotic pathways - a
  toxic gain of function on top of the channel loss. The SPG44 allele p.I33M does neither: it
  traffics normally, forms gap junction plaques at cell borders like wild-type Cx47, and shows
  no UPR or apoptotic activation. What it does lose is channel function - it fails to form
  functional homotypic channels, and the heterotypic I33M/Cx43 channels it does form open only
  under a large transjunctional voltage difference that is unlikely to occur physiologically.

  So the mechanism curated here is a comparatively clean loss of panglial coupling without the
  proteotoxic arm, and the clinical result is correspondingly milder: late onset, slowly
  progressive complicated spastic paraplegia with normal or near-normal psychomotor development,
  walking preserved into adulthood, and - diagnostically important - no nystagmus, which is a
  cardinal PMLD1 sign.

  The genotype-phenotype relationship is nevertheless not clean, and the entry says so rather
  than tidying it. In the second reported family a single homozygous GJC2 variant produced a
  complicated HSP in the proband and a full HLD2 phenotype in both of his sisters. One genotype,
  two diagnoses, one sibship. Any account of SPG44 as "the mild GJC2 allele class" has to
  survive that observation, and at present nothing explains it.
disease_term:
  preferred_term: hereditary spastic paraplegia 44
  term:
    id: MONDO:0013179
    label: hereditary spastic paraplegia 44
parents:
- Hereditary Spastic Paraplegia
notes: >-
  Size of the evidence base, stated plainly. Two published families. The founding report
  (PMID:19056803) describes three affected individuals from one Italian family with homozygous
  p.I33M, and pairs the clinical description with scrape-loading and dual whole-cell patch-clamp
  assays of the mutant channel - so the genetic observation is small but the functional
  characterisation is direct. The second family (PMID:37915394) is Iranian, carries a different
  homozygous variant, and is explicitly described by its authors as "the second case of SPG44".
  A third report (PMID:31431325) extends the late-onset GJC2 spectrum to ataxia, pyramidal signs
  and parkinsonism without using the SPG44 label; it is cited here as spectrum evidence, not as
  a third SPG44 family.

  Allelic relationship. SPG44 and PMLD1/HLD2 are the same gene and, on current evidence, the
  same cell-biological lesion at different severity, plus a proteotoxic arm that SPG44 lacks.
  This entry is curated as a separate disease rather than a `has_subtypes` entry on a GJC2
  parent because the KB carries numbered SPG loci as individual entries and because MONDO
  assigns SPG44 a leaf term of its own; the allelic relationship is recorded in `genetic` and in
  the discussion rather than by merging the two.

  Nomenclature correction worth recording. `kb/modules/corticospinal_tract_axonopathy.yaml`
  states that myelin-formation HSPs "SPG2/PLP1, SPG42/GJC2" belong to `cns_myelin_failure`. The
  routing is right and this entry follows it, but the locus number is wrong: GJC2 is SPG44, not
  SPG42 (SPG42 is SLC33A1). Reported separately rather than fixed inside a curation PR.

  What is deliberately not here. There is no prevalence figure, because none has been published
  for SPG44 specifically and the only honest statement is a published-case count. There is no
  treatment beyond supportive care and counselling, because neither cited source makes a
  management recommendation for this disorder, and importing general HSP management would
  attribute to SPG44 guidance written for a heterogeneous group.

  Deep research: an OpenScientist report was generated for this disease and is committed
  alongside the entry. It was used as a lead source only - every snippet below is anchored to a
  PMID fetched into `references_cache/` and read directly. Its citation record was clean (18/18
  references resolved, zero confabulation) but its *ontology* record was not: of 20 term labels
  checked, 7 named a different term than the identifier resolves to, including
  `NCIT:C61725` given as "Baclofen" when it is Diltiazem, `NCIT:C1027` as "Botulinum Toxin"
  when it is Budesonide, `NCIT:C15342` as "Physical Therapy" when it is Transplantation, and
  `UBERON:0002718` as "corticospinal / pyramidal tracts" when it is the solitary tract. None of
  those identifiers is used in this entry. The report was nonetheless materially useful: the
  preclinical gene-therapy work and the brainstem-auditory-evoked-potential discriminator below
  came from it as leads and were then verified against the primary papers.
inheritance:
- name: Autosomal recessive
  description: >-
    Homozygous GJC2 missense variants in consanguineous or geographically isolated families.
    Heterozygous carriers are unaffected in both published families.
  inheritance_term:
    preferred_term: Autosomal recessive inheritance
    term:
      id: HP:0000007
      label: Autosomal recessive inheritance
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Here we describe three patients from one family with a novel recessively inherited mutation, 99C>G (predicted to cause an Ile>Met amino acid substitution; I33M) that causes a milder phenotype."
    explanation: States the recessive inheritance and the founding allele in the index family.
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "A novel homozygous variant, c.G14T:p.Ser5Ile, in the GJC2 gene was identified. The variant was co-segregated with the disease status in the family members."
    explanation: Independent family with homozygosity and formal co-segregation.
pathophysiology:
- name: Connexin-47 Channel Loss of Function
  description: >-
    Biallelic hypomorphic GJC2 missense variants leave connexin-47 protein present and correctly
    delivered but unable to conduct. In transfected cells the p.I33M protein forms gap junction
    plaques at cell borders indistinguishable from wild-type Cx47, yet fails to form functional
    homotypic channels in both scrape-loading and dual whole-cell patch-clamp assays.

    This is the node that separates SPG44 from PMLD1 and it is worth being precise about why.
    The severe PMLD1 alleles are ER-retained and, in primary oligodendrocytes, switch on the
    unfolded protein response and apoptosis - loss of channel plus a proteotoxic gain of
    function. The SPG44 allele shows wild-type-like distribution and no UPR or apoptotic
    activation. The lesion here is confined to conductance.
  conforms_to: "cns_myelin_failure#Oligodendrocyte-Lineage or Myelin-Membrane Insult"
  biological_scale: MOLECULAR
  genes:
  - preferred_term: GJC2
    term:
      id: hgnc:17494
      label: GJC2
  genetic_context:
    functional_impact_category: LOSS_OF_FUNCTION
    allele_type: VARIANT
    variant_origin: GERMLINE
    zygosity: HOMOZYGOUS
  molecular_functions:
  - preferred_term: connexin-47 gap junction channel activity
    modifier: LOSS_OF_FUNCTION
    term:
      id: GO:0005243
      label: gap junction channel activity
  cellular_components:
  - preferred_term: gap junction plaque at the oligodendrocyte membrane
    term:
      id: GO:0005921
      label: gap junction
  downstream:
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The mutant protein forms gap junction plaques at cell borders similar to wild-type (WT) Cx47 in transfected cells, but fails to form functional homotypic channels in scrape-loading and dual whole-cell patch clamp assays."
    explanation: >-
      Two orthogonal assays establish that trafficking is preserved while conductance is lost -
      the precise shape of this node's claim.
  - reference: PMID:35276347
    reference_title: "Activation of the unfolded protein response by Connexin47 mutations associated with Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: IN_VITRO
    snippet: "the milder SPG44 associated mutation p.I33M shows a wild-type-like subcellular distribution and no activation of the UPR or apoptotic pathways"
    explanation: >-
      Supports confining this node to channel loss of function, by ruling out in primary
      oligodendrocytes the ER-retention and proteotoxic arm that the PMLD1 alleles show.
      Recorded as INDIRECT because the result is an exclusion - it establishes what the SPG44
      allele does not do, from which the narrower mechanism follows.
- name: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
  description: >-
    Cx47 is the oligodendrocyte partner in the panglial network: Cx47/Cx43 channels join
    oligodendrocytes to astrocytes, and Cx47 also contributes to oligodendrocyte-oligodendrocyte
    coupling. The SPG44 allele does form overlapping plaques and channels with Cx43, but those
    channels open only when a large voltage difference is applied across the paired cells - a
    condition the founding authors judge unlikely to be met physiologically. The functional
    result is therefore the same disruption of astrocyte-oligodendrocyte coupling that the
    ER-retained PMLD1 mutants cause, reached by a different molecular route.

    That this coupling is what matters, rather than Cx47 protein presence, is what the mouse
    genetics show: removing Cx47 alone leaves the animal essentially well, while removing Cx47
    together with the astrocytic or the second oligodendrocytic connexin abolishes
    oligodendrocyte-to-astrocyte coupling and produces overt myelin disease.
  biological_scale: CELLULAR
  cell_types:
  - preferred_term: oligodendrocyte
    term:
      id: CL:0000128
      label: oligodendrocyte
  - preferred_term: astrocyte
    term:
      id: CL:0000127
      label: astrocyte
  molecular_functions:
  - preferred_term: heterotypic Cx47/Cx43 gap junction channel activity
    modifier: DECREASED
    term:
      id: GO:0005243
      label: gap junction channel activity
  downstream:
  - target: CNS Hypomyelination and Myelin Instability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "These channels probably do not function under physiological conditions, suggesting that Cx47/Cx43 channels between astrocytes and oligodendrocytes are disrupted, similar to the loss-of-function endoplasmic reticulum-retained Cx47 mutants that cause PMLD."
    explanation: >-
      The authors' own inference from the electrophysiology, with their hedges ("probably",
      "suggesting") kept inside the quote because they carry the strength of the claim.
  - reference: PMID:22649229
    reference_title: "Panglial gap junctional communication is essential for maintenance of myelin in the CNS."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: MODEL_ORGANISM
    snippet: "Biocytin injections revealed complete disruption of oligodendrocyte-to-astrocyte coupling in the white matter of 10- to 15-d-old Cx30/Cx47 double-deficient mice, while oligodendrocyte-to-oligodendrocyte coupling was maintained."
    explanation: >-
      Demonstrates directly that losing Cx47 in combination severs the oligodendrocyte-astrocyte
      arm specifically. INDIRECT because the mouse genotype is a double knockout, not the human
      hypomorphic missense state.
- name: CNS Hypomyelination and Myelin Instability
  description: >-
    Loss of panglial coupling leaves the CNS myelin sheath deficient. In the SPG44 family, brain
    MRI and MR spectroscopy were consistent with a hypomyelinating leukoencephalopathy - the
    same imaging class as PMLD1, at lower severity. In mice, the corresponding lesion is
    vacuolation of myelinated fibres, most conspicuous in the optic nerve where oligodendrocytes
    first contact axons, and it worsens sharply when a second connexin is removed.
  conforms_to: "cns_myelin_failure#Deficient or Unstable CNS Myelin Sheath"
  biological_scale: TISSUE
  biological_processes:
  - preferred_term: central nervous system myelination
    modifier: DECREASED
    term:
      id: GO:0022010
      label: central nervous system myelination
  downstream:
  - target: Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: CNS Hypomyelination on MRI
    causal_link_type: DIRECT
    description: >-
      The imaging phenotype is the direct radiological readout of this node, not a separate
      consequence of it.
  - target: Ataxia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Hypomyelination is not confined to the corticospinal tracts, and the late-onset GJC2
      patients who show prominent ataxia show it alongside the same distinctive hypomyelinating
      MRI pattern. The intermediates between diffuse hypomyelination and a cerebellar syndrome
      are not established, which is why this link is INDIRECT_UNKNOWN_INTERMEDIATES rather than
      DIRECT.
  - target: Parkinsonism
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
    description: >-
      Reported in one sibling of the late-onset Turkish family, alongside the same MRI pattern.
      A single individual, so the link is drawn but weakly.
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI and MR spectroscopy imaging were consistent with a hypomyelinating leukoencephalopathy."
    explanation: The human tissue-level finding, from imaging in the index family.
  - reference: PMID:12805295
    reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Electron microscopic analysis of CNS white matter in Cx47-deficient mice revealed a conspicuous vacuolation of nerve fibers, particularly at the site of the optic nerve where axons are first contacted by oligodendrocytes and myelination starts."
    explanation: >-
      Ultrastructural myelin pathology attributable to Cx47 loss alone, in the compartment this
      node names.
- name: Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
  description: >-
    The clinical endpoint. Deficient myelination of long descending motor tracts produces a
    late-onset, slowly progressive complicated spastic paraplegia. What distinguishes it from
    the PMLD1 course is what is preserved: psychomotor development is normal or near-normal,
    walking is retained through adulthood, and nystagmus - a cardinal PMLD1 sign - is absent.
  biological_scale: ORGANISM
  downstream:
  - target: Progressive Spastic Paraplegia
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus."
    explanation: >-
      The complete clinical description of the founding family, including the three preserved
      features that separate SPG44 from PMLD1 at the bedside.
phenotypes:
- name: Progressive Spastic Paraplegia
  category: Neurologic
  description: >-
    The defining feature: a complicated spastic paraplegia, late in onset and slowly
    progressive, present in all three individuals of the founding family and in the proband of
    the second family.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: Spastic paraplegia
    term:
      id: HP:0001258
      label: Spastic paraplegia
    clinical_course: PROGRESSIVE
    onset:
      onset_category: ADULT
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus."
    explanation: Direct statement of the phenotype, its onset and its course in all three affected individuals.
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the proband presented a complicated form of HSP, whereas both his affected sisters presented a HLD2 phenotype"
    explanation: >-
      The second family's proband, and simultaneously the observation that the same genotype
      produced HLD2 in his sisters.
- name: CNS Hypomyelination on MRI
  category: Neurologic
  description: >-
    Brain MRI and MR spectroscopy consistent with hypomyelinating leukoencephalopathy. This is
    the finding that should prompt GJC2 testing in a patient presenting as HSP, and the second
    family's authors make exactly that recommendation.
  frequency: VERY_FREQUENT
  phenotype_term:
    preferred_term: CNS hypomyelination
    term:
      id: HP:0003429
      label: CNS hypomyelination
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "MRI and MR spectroscopy imaging were consistent with a hypomyelinating leukoencephalopathy."
    explanation: The imaging finding in the founding family.
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the screening of GJC2 in patients with HSP or HSP-like phenotypes especially with hypomyelination in their brain MRI is recommended"
    explanation: >-
      Ties the imaging phenotype to a testing recommendation, which is the practical reason to
      record it separately from the motor phenotype.
- name: Ataxia
  category: Neurologic
  description: >-
    Part of the complicated presentation. Prominent ataxia together with pyramidal disturbance
    is described in the late-onset GJC2 siblings reported by Kuipers and colleagues, who were
    not labelled SPG44 but carry the same allelic class and the same distinctive hypomyelinating
    MRI pattern.
  frequency: OCCASIONAL
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:31431325
    reference_title: "Late-onset phenotype associated with a homozygous GJC2 missense mutation in a Turkish family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings confirm and further expand the late-onset phenotypes of GJC2 mutations, to include prominent ataxia, pyramidal disturbances and mild parkinsonism, and confirm the distinctive associated MRI pattern."
    explanation: >-
      Ataxia in the late-onset GJC2 spectrum. Frequency is OCCASIONAL rather than higher because
      the founding SPG44 family is not described as ataxic and this comes from a separate family
      reported under a different label.
- name: Parkinsonism
  category: Neurologic
  description: >-
    Mild parkinsonism, reported in one of the two late-onset GJC2 siblings described by Kuipers
    and colleagues. A single individual, in a family reported under the late-onset GJC2 label
    rather than as SPG44, so this is at the edge of what this entry should claim - recorded
    because the observation is verified and because a GJC2 patient presenting with parkinsonism
    is the kind of thing a differential should be able to find.
  frequency: VERY_RARE
  phenotype_term:
    preferred_term: Parkinsonism
    term:
      id: HP:0001300
      label: Parkinsonism
    severity: MILD
  evidence:
  - reference: PMID:31431325
    reference_title: "Late-onset phenotype associated with a homozygous GJC2 missense mutation in a Turkish family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Our findings confirm and further expand the late-onset phenotypes of GJC2 mutations, to include prominent ataxia, pyramidal disturbances and mild parkinsonism, and confirm the distinctive associated MRI pattern."
    explanation: >-
      The same sentence that carries the ataxia claim. There are too few published patients for
      any numeric frequency band to be read literally - the whole late-onset GJC2 literature is
      single digits - so no percentage is claimed here. VERY_RARE records that parkinsonism is a
      singular, non-core observation: one individual, in one family, reported under the
      late-onset GJC2 label rather than as SPG44. The sibling asymmetry - the abstract's
      OBJECTIVE section attributes parkinsonism to one of the two siblings where ataxia and
      pyramidal disturbances are attributed to both - is why it is not banded alongside ataxia,
      and is not itself the frequency.
genetic:
- name: GJC2
  notes: >-
    Encodes connexin-47 (Cx47), the oligodendrocyte gap-junction protein that pairs with
    astrocytic Cx43 and contributes to oligodendrocyte-oligodendrocyte coupling. The gene is
    also written GJA12 in the older literature, including in the title of the founding SPG44
    report.

    The allelic series is the point of interest and is unusually well characterised at the
    protein level. Severe PMLD1/HLD2 alleles (p.P87S, p.Y269D, p.M283T) are retained in the ER
    and trigger the UPR and apoptosis in primary oligodendrocytes. The SPG44 allele p.I33M
    traffics normally and triggers neither, losing only channel function. Two different failure
    modes of one protein, with the milder disease corresponding to the allele that lacks the
    proteotoxic arm.

    That correspondence is real but not deterministic. In the second SPG44 family, one
    homozygous variant produced complicated HSP in the proband and HLD2 in both sisters, so
    allele class alone does not fix the phenotype.

    One further allelic association is worth flagging so a reader searching the gene does not
    conflate it with this disease: separate GJC2 variants are associated with autosomal
    dominant hereditary lymphedema, acting on lymphatic endothelium rather than
    oligodendrocytes. That is a different inheritance pattern, a different tissue and a
    different mechanism, and it is not part of the SPG44 phenotype. It is recorded as a
    curator's note rather than as an evidence-backed claim, because no source cited in this
    entry establishes it.
  relationship_type: CAUSATIVE
  gene_term:
    preferred_term: GJC2
    term:
      id: hgnc:17494
      label: GJC2
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Thus, GJA12/GJC2 mutations can result in a milder phenotype than previously appreciated"
    explanation: >-
      The authors' own summary of the gene-disease relationship. Deliberately cut at the comma:
      the rest of that sentence is an in-vitro statement about what the I33M protein may still
      do, which is a different claim with a different evidence source, and it is quoted
      separately in the model-mismatch discussion.
  variants:
  - name: c.99C>G (p.I33M)
    description: >-
      Homozygous missense variant in the founding Italian family. Traffics and forms plaques
      like wild-type Cx47 but is channel-dead as a homotypic channel; heterotypic I33M/Cx43
      channels open only at large transjunctional voltages.
    evidence:
    - reference: PMID:19056803
      reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
      supports: SUPPORT
      evidence_source: IN_VITRO
      snippet: "I33M forms overlapping gap junction plaques and functional channels with Cx43, however, I33M/Cx43 channels open only when a large voltage difference is applied to paired cells."
      explanation: The electrophysiological characterisation of the founding allele.
  - name: c.14G>T (p.S5I)
    description: >-
      Novel homozygous missense variant in the second, Iranian family, co-segregating with
      disease. The proband had complicated HSP; two sisters homozygous for the same variant had
      HLD2.
    evidence:
    - reference: PMID:37915394
      reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "A novel homozygous variant, c.G14T:p.Ser5Ile, in the GJC2 gene was identified. The variant was co-segregated with the disease status in the family members."
      explanation: Identifies the second family's allele and its co-segregation.
prevalence:
- population: Worldwide (published cases)
  measure_type: CASES_IN_LITERATURE
  prevalence_class: ULTRA_RARE
  notes: >-
    Two families in total. Three affected individuals in the founding Italian family, and one
    proband in the second, Iranian family - whose own authors state that the HSP-GJC2
    correlation had been reported only once before them. No population prevalence estimate for
    SPG44 has been published, and none is asserted here.
  evidence:
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Up to now, correlation between HSP and GJC2 variants has been reported once. Here, the second case of SPG44 was identified that emphasizes on GJC2 as a HSP-causing gene."
    explanation: >-
      Establishes the published-case count directly: one prior report, this being the second.
progression:
- phase: Onset
  age_range: late onset, after normal or near-normal psychomotor development
  notes: >-
    Unlike PMLD1, which presents in infancy with nystagmus and psychomotor delay, SPG44 begins
    after development has proceeded normally or near-normally. The onset difference is as much
    a discriminator as the severity difference.
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus."
    explanation: States the late onset and the preserved early development.
- phase: Established disease
  notes: >-
    Slowly progressive, with walking capability preserved through adulthood in all three
    individuals of the founding family. No published SPG44 patient has lost ambulation, but with
    two families and no longitudinal cohort this is an absence of reported progression rather
    than a demonstrated plateau.
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood"
    explanation: The course and the functional outcome, as far as the founding report records them.
diagnosis:
- name: GJC2 Sequencing Prompted by Hypomyelinating MRI
  description: >-
    The productive diagnostic route is an HSP or HSP-like presentation whose brain MRI shows
    hypomyelination, followed by GJC2 sequencing. This is the recommendation the second family's
    authors make explicitly, and it matters because a patient labelled HSP will not usually have
    a leukodystrophy gene tested.
  evidence:
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "the screening of GJC2 in patients with HSP or HSP-like phenotypes especially with hypomyelination in their brain MRI is recommended"
    explanation: The authors' explicit testing recommendation.
  - reference: PMID:31431325
    reference_title: "Late-onset phenotype associated with a homozygous GJC2 missense mutation in a Turkish family."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Brain MRI showed hyperintense signal in T2-weighted images in the internal capsule and subcortical and periventricular white matter, consistent with hypomyelination."
    explanation: >-
      Describes the imaging pattern concretely, in an independent late-onset GJC2 family, which
      is what makes the MRI-first strategy actionable.
- name: Brainstem Auditory Evoked Potentials to Separate GJC2 from PLP1 Disease
  description: >-
    GJC2 disease and PLP1-related Pelizaeus-Merzbacher disease are described as almost
    indistinguishable clinically and radiologically, and both can present as a hypomyelinating
    leukoencephalopathy with spasticity. Brainstem auditory evoked potentials separate them:
    waves III-V were absent in every PLP1 patient studied and clearly recordable in most GJC2
    patients. In a patient whose pedigree is compatible with either, this is a cheap test that
    points at the right gene first.

    The same series found nerve conduction studies normal in all PLP1 patients and indicating
    mild peripheral neuropathy in 2 of 10 GJC2 patients - worth knowing when interpreting a
    mildly abnormal NCS, though those patients carried the severe PMLD alleles rather than the
    SPG44 ones and no peripheral neuropathy is reported in either published SPG44 family.
  evidence:
  - reference: PMID:20513814
    reference_title: "Clinical neurophysiology in GJA12-related hypomyelination vs Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "In brainstem auditory EP, waves III-V were absent in all patients with PMD, but clearly recordable in 11 of 13 investigations in 8 patients with PMLD."
    explanation: >-
      The discriminating result. INDIRECT for SPG44 because the GJC2 patients studied had PMLD
      rather than SPG44; the inference is that a test separating GJC2 from PLP1 disease does so
      by the gene, not by the severity, and the entry says so rather than implying the study
      included SPG44 patients.
  - reference: PMID:20513814
    reference_title: "Clinical neurophysiology in GJA12-related hypomyelination vs Pelizaeus-Merzbacher disease."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "NCS were normal in all patients with PMD and indicated mild peripheral neuropathy in only 2 of 10 patients with PMLD."
    explanation: >-
      The peripheral-nerve finding, at the frequency the study reports. INDIRECT for the same
      reason: these are PMLD patients, and no SPG44 patient has been reported with neuropathy.
treatments:
- name: Genetic Counseling
  description: >-
    Both published families are homozygous for private missense variants, so recurrence-risk
    counselling and carrier testing are directly indicated. The second family gives counselling
    an unusually concrete content: siblings homozygous for the same variant had markedly
    different phenotypes, so a recurrence cannot be predicted to be mild.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Genetic Counseling
    term:
      id: NCIT:C15240
      label: Genetic Counseling
  evidence:
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical evaluation of all patients showed two distinct GJC2-related phenotypes in this family; the proband presented a complicated form of HSP, whereas both his affected sisters presented a HLD2 phenotype."
    explanation: >-
      The intrafamilial discordance that makes prognostic counselling on genotype alone
      unsupportable in this disorder.
- name: Symptomatic Management of Spasticity
  description: >-
    No disease-modifying therapy exists. Care follows general hereditary spastic paraplegia
    practice - physiotherapy, mobility support, antispastic measures. Recorded with no specific
    agent bound, because neither cited source makes a drug recommendation for SPG44.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
    description: >-
      Addresses the functional consequence only. Nothing available acts on the coupling defect
      upstream of it.
  notes: >-
    Deliberately thin, and the thinness is the finding. Both SPG44 reports are gene-discovery
    and mechanism papers with no management section, and no GeneReviews chapter covers SPG44.
    This entry does not import management text from the general HSP literature.
  evidence:
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    directness: INDIRECT
    evidence_source: HUMAN_CLINICAL
    snippet: "preserved walking capability through adulthood"
    explanation: >-
      Establishes the ambulatory status that supportive care is aimed at maintaining. INDIRECT
      because no cited source states a management recommendation for this disorder; the claim
      that supportive care is what is available follows from the absence of anything else, not
      from this sentence.
- name: Oligodendrocyte-Targeted AAV-GJC2 Gene Therapy (preclinical only)
  description: >-
    NOT A TREATMENT FOR PATIENTS. A single intracerebral injection of AAV.MBP.Cx47myc - the
    GJC2 coding sequence under the myelin basic protein promoter, so expression is restricted to
    oligodendrocytes - at postnatal day 10 improved motor performance and coordination and
    prolonged survival in Cx32/Cx47 double-knockout mice, with improvement in demyelination,
    oligodendrocyte apoptosis, inflammation and astrogliosis, and re-established gap-junctional
    dye transfer between oligodendrocytes.

    The mechanistic rationale is unusually direct for SPG44 in particular. The disease node this
    acts on is loss of channel function, and the SPG44 allele has been shown not to carry the
    ER-retention and proteotoxic arm that the severe alleles do - so there is no misfolded
    species to clear before a replacement connexin can work. A replacement strategy is matched
    to a clean loss of function in a way it would not be to a toxic gain of function.

    Two things keep this firmly preclinical. No human has been treated and no trial exists. And
    the model treated is the Cx32/Cx47 double knockout, which corresponds to severe PMLD1, not
    to the mild SPG44 course - so the rescue is demonstrated against a disease severity that
    SPG44 patients do not have.
  therapeutic_modality: GENE_THERAPY
  treatment_term:
    preferred_term: Gene Therapy
    term:
      id: NCIT:C15238
      label: Gene Therapy
  target_mechanisms:
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    description: >-
      Restores oligodendrocyte gap-junctional connectivity directly, which is the node one step
      below the genetic lesion. Dye transfer between oligodendrocytes was re-established in
      treated animals, so the intended molecular effect was measured rather than assumed.
  evidence:
  - reference: PMID:28100454
    reference_title: "Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Application of this oligodendrocyte-targeted somatic gene therapy at postnatal Day 10 in groups of double knockout mice, a well characterized model of hypomyelinating leukodystrophy-2, resulted in significant improvement in motor performance and coordination at 1 month of age in treated compared to mock-treated mice, as well as prolonged survival."
    explanation: >-
      The preclinical rescue result, in mouse, with the treatment age stated. Graded
      MODEL_ORGANISM because it is entirely a mouse result and the entry does not represent it
      as anything else.
  - reference: PMID:25524707
    reference_title: "Transgenic replacement of Cx32 in gap junction-deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our study confirms that loss of oligodendrocyte GJs has cell autonomous effects and that re-establishment of GJ connectivity by replacement of least one GJ protein provides correction of the leukodystrophy phenotype."
    explanation: >-
      The genetic proof of principle that preceded the vector work, and the reason to think the
      target is correct: restoring gap-junctional connectivity by any oligodendrocytic connexin
      corrects the phenotype, so the defect is the coupling rather than Cx47 itself.
animal_models:
- name: Cx47-null mouse (Gjc2 single knockout)
  species: Mouse
  genotype: Cx47-null (Gjc2 coding DNA replaced by EGFP reporter)
  publication: PMID:12805295
  description: >-
    Germline replacement of the Cx47 coding sequence with EGFP under the endogenous promoter.
    The reporter also settled where Cx47 is expressed - predominantly oligodendrocytes in highly
    myelinated CNS tissue, correcting an earlier claim of neuronal expression.
  modeled_mechanisms:
  - target: CNS Hypomyelination and Myelin Instability
    relationship: PARTIALLY_RECAPITULATES
    fidelity: MODERATE
    description: >-
      Reproduces the myelin lesion at the ultrastructural level - conspicuous vacuolation of
      nerve fibres in CNS white matter, maximal in the optic nerve.
    limitations: >-
      The lesion is subclinical. It is visible by electron microscopy in an animal with no
      overt phenotype, so the model captures the myelin abnormality without the disease.
    readouts:
    - name: Myelinated fibre vacuolation on electron microscopy
      target: CNS Hypomyelination and Myelin Instability
      direction: INCREASED
      interpretation: Ultrastructural correlate of the myelin node, attributable to Cx47 loss alone.
      evidence:
      - reference: PMID:12805295
        reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Electron microscopic analysis of CNS white matter in Cx47-deficient mice revealed a conspicuous vacuolation of nerve fibers, particularly at the site of the optic nerve where axons are first contacted by oligodendrocytes and myelination starts."
        explanation: Reports the histological measurement behind this readout.
    evidence:
    - reference: PMID:12805295
      reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Cx47 protein was detected by Western blot analysis after immunoprecipitation in CNS tissues of wild-type mice but not in heart or Cx47-deficient tissues."
      explanation: >-
        Supports treating this model as informative for the myelin node by establishing that it
        is a genuine protein null rather than a knockdown, which is the precondition for reading
        its myelin lesion as a Cx47 loss-of-function phenotype.
  - target: Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
    relationship: FAILS_TO_RECAPITULATE
    fidelity: LOW
    description: >-
      Cx47-null mice are fertile and show no obvious morphological or behavioural abnormality.
      The single knockout does not produce the human motor disease.
    limitations: >-
      This is a species-level difference in connexin redundancy, not a technical failure of the
      model. Mouse oligodendrocytes retain Cx32 and mouse astrocytes retain Cx30 and Cx43, and
      removing a second connexin alongside Cx47 does produce overt disease - action tremor and
      death by around 51 days in Cx32/Cx47 double nulls. Any inference from a single-connexin
      mouse to a human GJC2 patient therefore has to account for a redundancy the human does not
      obviously share, and this entry does not use the single knockout as evidence for or
      against the human motor phenotype.
    readouts:
    - name: Overt morphological and behavioural phenotype
      target: Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
      direction: UNCHANGED
      interpretation: >-
        No detectable phenotype in the single knockout - a real negative result, and the reason
        the fidelity here is LOW.
      evidence:
      - reference: PMID:12805295
        reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
        supports: REFUTE
        evidence_source: MODEL_ORGANISM
        snippet: "Homozygous mutant mice were fertile and showed no obvious morphological or behavioral abnormalities."
        explanation: >-
          Refutes the proposition that Cx47 loss alone reproduces the human motor phenotype in
          the mouse.
    evidence:
    - reference: PMID:12805295
      reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
      supports: REFUTE
      evidence_source: MODEL_ORGANISM
      snippet: "Homozygous mutant mice were fertile and showed no obvious morphological or behavioral abnormalities."
      explanation: >-
        The substantiating negative result required for a FAILS_TO_RECAPITULATE link: the model
        is not informative for the clinical motor node.
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    relationship: MEASURES
    fidelity: MODERATE
    description: >-
      The EGFP reporter knock-in localised Cx47 expression to oligodendrocytes in highly
      myelinated CNS tissue, which is what licenses treating an oligodendrocyte gap-junction
      defect as the cell of origin in the human disease.
    limitations: >-
      An expression measurement, not a disease measurement. It establishes where the protein is,
      not what its loss does.
    readouts:
    - name: Cell-type localisation of Cx47 expression by EGFP reporter
      target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
      interpretation: >-
        Places Cx47 in oligodendrocytes rather than neurons. `direction` is deliberately
        omitted: the measurement was made, but it is a localisation rather than an increase or
        decrease, and ModelReadoutDirectionEnum has no value for a non-directional result.
      evidence:
      - reference: PMID:12805295
        reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Cx47 was mainly expressed in oligodendrocytes in highly myelinated CNS tissues and in few calcium-binding protein S100beta subunit-positive cells but not in neurons or peripheral sciatic nerve."
        explanation: Reports the expression measurement behind this readout.
    evidence:
    - reference: PMID:12805295
      reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "This corrects our previous conclusion that Cx47 mRNA is expressed in brain and spinal cord neurons (Teubner et al., 2001)."
      explanation: >-
        Worth quoting for provenance: the same group is retracting its own earlier localisation,
        which is why this measurement rather than the older one should be relied on.
- name: Cx32/Cx47 double-null mouse
  species: Mouse
  genotype: Gjb1-null; Gjc2-null (Cx32/Cx47 double-deficient)
  publication: PMID:12805295
  description: >-
    Removing the second oligodendrocytic connexin alongside Cx47 converts the subclinical
    single-knockout lesion into overt, lethal white-matter disease.
  modeled_mechanisms:
  - target: CNS Hypomyelination and Myelin Instability
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Action tremor with death at a mean of 51 days and much more abundant white-matter
      vacuolation than the single knockout.
    limitations: >-
      Two genes are removed, and the human disease involves one. The model demonstrates that
      oligodendrocytic gap-junctional coupling is what matters, but its severity and lethality
      are not the SPG44 course, which is late-onset and compatible with adult ambulation.
    readouts:
    - name: White-matter fibre vacuolation relative to single knockout
      target: CNS Hypomyelination and Myelin Instability
      direction: INCREASED
      interpretation: Dose-dependence of the myelin lesion on total oligodendrocytic connexin loss.
      evidence:
      - reference: PMID:12805295
        reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "The central white matter of these double-deficient mice exhibited much more abundant vacuolation in nerve fibers than mice deficient only in Cx47."
        explanation: Reports the comparative histological measurement behind this readout.
    evidence:
    - reference: PMID:12805295
      reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Initial analyses of Cx32/Cx47-double-deficient mice showed that these mice developed an action tremor and died on average at 51 d after birth."
      explanation: Supports treating this model as informative for the myelin node, with an overt phenotype.
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    relationship: RESCUES
    fidelity: MODERATE
    description: >-
      The same model is the platform on which restoring gap-junctional coupling has been shown
      to correct the disease - twice, by two different routes. Transgenic oligodendrocytic
      expression of human Cx32 rescued the severe demyelinating phenotype and prevented early
      mortality; an AAV vector delivering Cx47 under the myelin basic protein promoter,
      injected once at postnatal day 10, improved motor performance and survival and
      re-established dye transfer between oligodendrocytes.
    limitations: >-
      Both rescues are in the double knockout, which is a model of severe PMLD1 rather than of
      SPG44, and both intervene at postnatal day 10 or earlier - before the human disease would
      be diagnosed. What they establish for SPG44 is that the coupling defect is correctable in
      principle and that the target is the coupling rather than Cx47 protein identity; they do
      not establish a therapeutic window for a late-onset human disease.
    readouts:
    - name: Oligodendrocyte gap-junctional dye transfer after AAV-Cx47
      target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
      direction: RESTORED
      interpretation: >-
        Direct confirmation that the intended molecular effect was achieved, not just a
        behavioural improvement.
      evidence:
      - reference: PMID:28100454
        reference_title: "Gene therapy targeting oligodendrocytes provides therapeutic benefit in a leukodystrophy model."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Functional dye transfer analysis confirmed the re-establishment of oligodendrocyte gap junctional connectivity in treated as opposed to untreated mice."
        explanation: Reports the coupling measurement behind this readout.
    - name: Survival and motor performance after transgenic Cx32 replacement
      target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
      direction: RESTORED
      interpretation: >-
        Genetic rather than vector-delivered rescue, and by a different connexin - which is what
        makes the target the coupling rather than Cx47 specifically.
      evidence:
      - reference: PMID:25524707
        reference_title: "Transgenic replacement of Cx32 in gap junction-deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "transgenic expression of hCx32 rescued the severe early phenotype of CNS demyelination in Cx32/Cx47dKO mice, resulting in marked improvement of behavioral abnormalities at 1 month of age, and preventing the early mortality"
        explanation: Reports the survival and behavioural rescue behind this readout.
    evidence:
    - reference: PMID:25524707
      reference_title: "Transgenic replacement of Cx32 in gap junction-deficient oligodendrocytes rescues the phenotype of a hypomyelinating leukodystrophy model."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Our study confirms that loss of oligodendrocyte GJs has cell autonomous effects and that re-establishment of GJ connectivity by replacement of least one GJ protein provides correction of the leukodystrophy phenotype."
      explanation: >-
        Supports treating this model as informative for the coupling node in the rescue
        direction, and states the cell-autonomy conclusion that the gene-therapy strategy rests on.
- name: Cx30/Cx47 double-null mouse
  species: Mouse
  genotype: Gjb6-null; Gjc2-null (Cx30/Cx47 double-deficient)
  publication: PMID:22649229
  description: >-
    Removes the astrocytic partner connexin instead of the second oligodendrocytic one, and so
    isolates the oligodendrocyte-to-astrocyte arm of panglial coupling specifically. This is the
    closest experimental analogue of the coupling defect inferred in SPG44.
  modeled_mechanisms:
  - target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Oligodendrocyte-to-astrocyte coupling is completely disrupted while
      oligodendrocyte-to-oligodendrocyte coupling is maintained - the precise selectivity this
      node asserts for the human allele.
    limitations: >-
      A double knockout of two connexins, one of them astrocytic, standing in for a human
      hypomorphic missense allele in the oligodendrocytic connexin alone. The coupling defect is
      the shared feature; the genetic architecture is not.
    readouts:
    - name: Oligodendrocyte-to-astrocyte biocytin coupling
      target: Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
      direction: ABOLISHED
      interpretation: >-
        Direct measurement of the coupling loss, with the oligodendrocyte-oligodendrocyte arm
        preserved as an internal control.
      evidence:
      - reference: PMID:22649229
        reference_title: "Panglial gap junctional communication is essential for maintenance of myelin in the CNS."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Biocytin injections revealed complete disruption of oligodendrocyte-to-astrocyte coupling in the white matter of 10- to 15-d-old Cx30/Cx47 double-deficient mice, while oligodendrocyte-to-oligodendrocyte coupling was maintained."
        explanation: Reports the dye-coupling measurement behind this readout.
    evidence:
    - reference: PMID:22649229
      reference_title: "Panglial gap junctional communication is essential for maintenance of myelin in the CNS."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "show that both connexins are required for maintenance of myelin"
      explanation: Supports treating this model as informative for the coupling node.
  - target: CNS Hypomyelination and Myelin Instability
    relationship: RECAPITULATES
    fidelity: MODERATE
    description: >-
      Severe vacuolation and myelination defects in all CNS white-matter tracts, with reduced
      oligodendrocyte numbers, astrogliosis and microglial activation, plus motor impairment and
      early death in about 40% of animals.
    limitations: >-
      Far more severe than SPG44 and closer to PMLD1 in course. Useful as evidence that coupling
      loss causes myelin failure, not as a model of the SPG44 severity.
    readouts:
    - name: White-matter vacuolation and myelination defects
      target: CNS Hypomyelination and Myelin Instability
      direction: INCREASED
      interpretation: The myelin consequence of severed panglial coupling.
      evidence:
      - reference: PMID:22649229
        reference_title: "Panglial gap junctional communication is essential for maintenance of myelin in the CNS."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Histological and ultrastructural analyses revealed severe vacuolization and myelination defects in all white matter tracts of the CNS."
        explanation: Reports the histological measurement behind this readout.
    - name: Myelin sheath thickness in surviving adults
      target: CNS Hypomyelination and Myelin Instability
      direction: DECREASED
      interpretation: >-
        The lesion persists rather than resolving in animals that survive, which is what makes
        it a maintenance failure rather than a developmental delay.
      evidence:
      - reference: PMID:22649229
        reference_title: "Panglial gap junctional communication is essential for maintenance of myelin in the CNS."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Vacuole formation and thinner myelin sheaths were evident also with adult surviving double-KO mice."
        explanation: Reports the adult ultrastructural measurement behind this readout.
    evidence:
    - reference: PMID:22649229
      reference_title: "Panglial gap junctional communication is essential for maintenance of myelin in the CNS."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "We observed early onset myelin pathology, and ∼40% of Cx30/Cx47 double-deficient animals died within 42 to 90 d after birth, accompanied by severe motor impairments."
      explanation: Supports treating this model as informative for the myelin node.
discussions:
- discussion_id: spg44_same_genotype_two_diagnoses
  kind: OPEN_QUESTION
  status: OPEN
  prompt: >-
    One homozygous GJC2 variant produced complicated hereditary spastic paraplegia in a proband
    and full hypomyelinating leukodystrophy 2 in both of his sisters. If allele class does not
    determine which GJC2 disease a patient gets, what does?
  attaches_to:
  - genetic#GJC2
  - pathophysiology#Connexin-47 Channel Loss of Function
  - disease#Hereditary Spastic Paraplegia 44
  rationale: >-
    The tidy account of GJC2 disease is a severity ladder set by allele class: ER-retained,
    UPR-activating alleles give infantile PMLD1/HLD2; a trafficking-competent but channel-dead
    allele gives late-onset SPG44. The functional work supports that ladder well - p.I33M shows
    wild-type-like distribution and no UPR or apoptotic activation, where p.P87S, p.Y269D and
    p.M283T show ER retention and both.

    The second SPG44 family breaks it. All three affected siblings are homozygous for the same
    novel c.14G>T (p.S5I) variant, and the proband has complicated HSP while both sisters have
    HLD2. Within one sibship, one genotype, two diagnoses. Their own authors read this as
    evidence for a shared pathophysiology across the GJC2 spectrum rather than as a challenge to
    the ladder, and both readings are available from the same observation.

    This is filed as an OPEN_QUESTION rather than a KNOWLEDGE_GAP because the relevant
    measurement has not merely been omitted - it is not clear what the measurement would be.
    Modifier alleles, differences in the astrocytic connexin partners, and stochastic
    developmental factors are all live candidates, and no source cited here distinguishes them.

    A practical consequence follows, and it is recorded in the counselling treatment entry: a
    recurrence in a family with a known "mild" GJC2 allele cannot be counselled as mild.
  evidence:
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Clinical evaluation of all patients showed two distinct GJC2-related phenotypes in this family; the proband presented a complicated form of HSP, whereas both his affected sisters presented a HLD2 phenotype."
    explanation: The discordance this discussion is about, within one sibship and one genotype.
  - reference: PMID:37915394
    reference_title: "Description of Phenotypic Heterogeneity in a GJC2-Related Family and Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Such intrafamilial phenotypic heterogeneity for GJC2 can emphasize on the shared pathophysiology of these disorders."
    explanation: >-
      The authors' own reading of the same fact, recorded because this entry does not adjudicate
      between it and the allele-ladder reading.
  - reference: PMID:35276347
    reference_title: "Activation of the unfolded protein response by Connexin47 mutations associated with Pelizaeus-Merzbacher-like disease."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "three PMLD1 associated mutants (p.P87S, p.Y269D and p.M283T) show ER retention of Cx47 and evidence of activation of the cellular stress (unfolded protein response, UPR) and apoptotic pathways"
    explanation: The allele-class ladder that the intrafamilial discordance has to be reconciled with.
- discussion_id: spg44_single_connexin_mouse_redundancy
  kind: HUMAN_MODEL_MISMATCH
  status: OPEN
  prompt: >-
    Cx47-null mice have vacuolated myelin but no overt phenotype, while humans homozygous for a
    channel-dead GJC2 allele develop progressive spastic paraplegia. Is the difference mouse
    connexin redundancy, or does the human allele do something a null does not?
  attaches_to:
  - animal_models#Cx47-null mouse (Gjc2 single knockout)
  - pathophysiology#Disrupted Oligodendrocyte-Astrocyte Panglial Coupling
  - pathophysiology#Corticospinal Tract Dysfunction and Progressive Spastic Paraparesis
  rationale: >-
    Evidence exists in the model; what is uncertain is whether it transfers.

    Established in mouse: deleting Cx47 alone leaves animals fertile and behaviourally normal
    with a purely ultrastructural myelin lesion. Deleting Cx47 together with the second
    oligodendrocytic connexin Cx32 gives action tremor and death at around 51 days. Deleting it
    together with the astrocytic Cx30 abolishes oligodendrocyte-to-astrocyte coupling, causes
    severe vacuolation in all white-matter tracts, and kills about 40% of animals within 42-90
    days. The mouse therefore needs two connexins removed to become ill.

    Established in human: two families homozygous for GJC2 missense alleles develop
    hypomyelinating leukoencephalopathy with progressive spastic paraplegia, from a single
    connexin lesion.

    Two readings are open and this entry does not choose. Either mouse oligodendrocytes are
    protected by a Cx32 redundancy that human oligodendrocytes do not have to the same degree -
    in which case the single-knockout null result says nothing about the human disease - or the
    human missense alleles are not simple nulls and exert an effect a null cannot. The second
    reading is specifically not excluded for SPG44 by the UPR work, which ruled out the
    ER-retention and apoptosis arm but not every possible non-channel function: the founding
    report ends by saying it is not known whether I33M retains a Cx47 function unrelated to
    forming functional channels.

    Filed as HUMAN_MODEL_MISMATCH rather than KNOWLEDGE_GAP because the model data exist and are
    good; the open question is their translational validity.
  evidence:
  - reference: PMID:12805295
    reference_title: "Connexin 47 (Cx47)-deficient mice with enhanced green fluorescent protein reporter gene reveal predominant oligodendrocytic expression of Cx47 and display vacuolized myelin in the CNS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Homozygous mutant mice were fertile and showed no obvious morphological or behavioral abnormalities."
    explanation: The mismatch itself - a single-connexin null mouse with no disease.
  - reference: PMID:22649229
    reference_title: "Panglial gap junctional communication is essential for maintenance of myelin in the CNS."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "probably caused by the upregulation of oligodendrocytic Cx32 in Cx30/Cx47 double-deficient mice"
    explanation: >-
      Names the compensating connexin explicitly, which is what makes the redundancy reading
      concrete rather than a general appeal to species difference.
  - reference: PMID:19056803
    reference_title: "Hereditary spastic paraplegia is a novel phenotype for GJA12/GJC2 mutations."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "whether I33M retains a function of Cx47 not directly related to forming functional gap junction channels is not known"
    explanation: >-
      The authors' explicit statement that the non-channel-function reading is open, which is why
      this discussion does not settle on redundancy alone.
  proposed_experiments:
  - experiment_id: exp_spg44_knockin_vs_null_mouse
    name: Knock-in of the human SPG44 allele versus Cx47 null, on a matched background
    description: >-
      Generate a Gjc2 p.I33M knock-in mouse and compare it directly with the existing Cx47 null
      for oligodendrocyte-astrocyte biocytin coupling, myelin ultrastructure, and motor
      behaviour. A knock-in that is worse than the null would show the human allele is not a
      simple loss of function; a knock-in indistinguishable from the null would leave species
      redundancy as the explanation for the mouse-human gap.
    would_support:
    - pathophysiology#Connexin-47 Channel Loss of Function
    supporting_outcome:
    - >-
      The p.I33M knock-in phenocopies the null, with coupling loss and subclinical myelin
      vacuolation only, supporting a pure loss-of-conductance mechanism whose mildness in mouse
      reflects Cx32 redundancy.
    refuting_outcome:
    - >-
      The p.I33M knock-in is more severely affected than the null, indicating the missense
      protein exerts an effect beyond loss of channel function and that the mechanism curated
      here is incomplete.
📚

References & Deep Research

Deep Research

1
OpenScientist ▸
Hereditary Spastic Paraplegia 44 (SPG44): Comprehensive Disease Characterization Report
openscientist-autonomous 18 citations 2026-08-30T21:01:06.711349

Hereditary Spastic Paraplegia 44 (SPG44): Comprehensive Disease Characterization Report

Disease: Hereditary Spastic Paraplegia 44 (SPG44) MONDO ID: MONDO:0013179 | OMIM (phenotype): 613206 | Category: Mendelian (autosomal recessive) Causal gene: GJC2 (= GJA12), connexin-47 (Cx47)

Summary

Hereditary Spastic Paraplegia 44 (SPG44) is an ultra-rare, autosomal recessive complicated hereditary spastic paraplegia caused by biallelic mutations in GJC2 (also known as GJA12), the gene encoding the oligodendrocyte gap-junction protein connexin-47 (Cx47). SPG44 occupies the mild end of a GJC2 allelic severity continuum whose severe pole is Pelizaeus–Merzbacher-like disease type 1 (PMLD1), also called hypomyelinating leukodystrophy 2 (HLD2, OMIM 608804). A third, mechanistically unrelated allelic disorder — autosomal dominant hereditary lymphedema type IC (LCRP1, OMIM 613480) — arises from other GJC2 variants affecting lymphatic endothelium. The landmark description of SPG44 (Orthmann-Murphy et al., 2009) reported three patients from one family homozygous for the GJC2 variant c.99C>G (p.Ile33Met, "I33M") who had late-onset, slowly progressive complicated spastic paraplegia with normal or near-normal psychomotor development, preserved walking through adulthood, no nystagmus, and MRI evidence of hypomyelinating leukoencephalopathy.

Mechanistically, SPG44 results from loss of functional Cx47 gap-junction channels, which disrupts oligodendrocyte–oligodendrocyte and oligodendrocyte–astrocyte ("panglial syncytium") coupling required to maintain CNS myelin. A key distinction from severe PMLD1 emerged from in-vitro work: severe PMLD1 mutants are retained in the endoplasmic reticulum (ER) and trigger the unfolded protein response (UPR) and apoptosis (a toxic gain-of-function component), whereas the mild SPG44 allele p.I33M shows wild-type-like subcellular distribution and a clean loss-of-function without ER stress or apoptosis. This mechanistic difference plausibly explains SPG44's comparatively benign, ambulation-preserving course.

There is no disease-modifying therapy for SPG44; management is symptomatic (baclofen, botulinum toxin, physiotherapy, orthotics). Proof-of-concept oligodendrocyte-targeted AAV-GJC2 gene therapy rescued pathology in Cx32/Cx47 double-knockout mice, and transgenic re-expression of connexins rescued the same model, validating a cell-autonomous, correctable loss-of-function mechanism. Prevention is limited to genetic counseling, carrier testing, and reproductive options (prenatal / preimplantation genetic testing) for known familial variants. Prognosis is favorable relative to PMLD1: the disorder is chronic, slowly progressive, and lifelong, but not typically fatal.

1. Disease Information

Overview. SPG44 is a form of complicated (syndromic) hereditary spastic paraplegia in which slowly progressive lower-limb spasticity is accompanied by a diffuse hypomyelinating leukoencephalopathy visible on brain MRI, together with variable cerebellar signs and, in a minority, mild peripheral neuropathy — while cognition and vision are largely spared. It is genetically defined by biallelic GJC2 mutations and is the mildest of the recognized GJC2-related CNS disorders.

Key identifiers.

Resource Identifier
MONDO MONDO:0013179
OMIM (phenotype) 613206 (Spastic paraplegia 44, autosomal recessive)
OMIM (gene) 608803 (GJC2)
Gene (HGNC) HGNC:8433 (GJC2)
NCBI Gene 57165
UniProt Q5T442 (Cx47 / GJC2_HUMAN)
Allelic disorders PMLD1/HLD2 (OMIM 608804); Lymphedema hereditary IC / LCRP1 (OMIM 613480)

Synonyms / alternative names. SPG44; spastic paraplegia type 44, autosomal recessive; GJC2/GJA12-related complicated hereditary spastic paraplegia. The gene is historically named GJA12 and currently GJC2.

Data provenance. Information is derived overwhelmingly from aggregated disease-level resources and small published case reports/family studies (the original Italian family and a subsequent Iranian family), plus mechanistic in-vitro and mouse-model literature — not from large EHR/individual-patient datasets, reflecting the disorder's extreme rarity.

2. Etiology

Causal factors. SPG44 is a monogenic, autosomal recessive genetic disorder caused by biallelic (homozygous or compound heterozygous) pathogenic variants in GJC2/GJA12 encoding connexin-47. There is no environmental, infectious, or acquired cause. The disease is fully explained by loss of Cx47 gap-junction function in oligodendrocytes. As stated in the landmark report, three patients from one family carried "a novel recessively inherited mutation, 99C>G (predicted to cause an Ile>Met amino acid substitution; I33M) that causes a milder phenotype" (PMID: 19056803).

Genetic risk factors. The sole risk determinant is the presence of two pathogenic GJC2 alleles. The originally described SPG44 allele is c.99C>G (p.Ile33Met, I33M) in the N-terminus; a novel homozygous variant c.G14T (p.Ser5Ile) was later reported in an Iranian family initially diagnosed as HSP (Ghasemi et al., 2023, PMID: 37915394). No modifier genes for SPG44 have been established.

Environmental risk / protective factors. None known or expected for a fully penetrant recessive Mendelian disorder. Consanguinity is an important epidemiologic enabler because it increases homozygosity for rare recessive alleles; reported families are frequently consanguineous (e.g., Iranian and Turkish GJC2 cohorts). No protective variants, dietary, or lifestyle factors have been identified.

Gene–environment interactions. No validated gene–environment interactions are described for SPG44.

3. Phenotypes

The core SPG44 phenotype (Orthmann-Murphy et al., 2009; p.I33M family) is late-onset, slowly progressive complicated spastic paraplegia with normal or near-normal psychomotor development, preserved independent walking into adulthood, and absence of nystagmus — distinguishing it from the allelic PMLD1. The original report states: "All three had a late-onset, slowly progressive, complicated spastic paraplegia, with normal or near-normal psychomotor development, preserved walking capability through adulthood, and no nystagmus" (PMID: 19056803).

Phenotype HPO term Type Onset / severity / course Frequency (SPG44)
Spastic paraplegia HP:0001258 Clinical sign Late-onset, slowly progressive Defining/near-universal
Lower-limb spasticity HP:0002061 Clinical sign Progressive High
Progressive spastic paraplegia HP:0007015 Clinical sign Slowly progressive High
Abnormal cerebral white matter morphology (hypomyelination) HP:0002500 Imaging/lab Present from early imaging Near-universal
Diffuse white matter abnormalities HP:0007204 Imaging/lab Diffuse pattern Near-universal
Cerebellar signs / ataxia HP:0001251 Clinical sign Variable, complicating Minority/variable
Dysarthria HP:0001260 Clinical sign Variable Minority
Mild peripheral neuropathy HP:0009830 Lab (NCS) Mild, minority ~2/10 in GJC2 PMLD series (NCS)

Notably spared: early nystagmus, significant cognitive impairment, and severe early psychomotor delay — features that characterize the more severe allelic PMLD1. Brainstem auditory evoked potentials (BAEP) are typically recordable in GJC2 disease (contrast with absent BAEP waves III–V in PLP1-related PMD). In a comparative neurophysiology series, "NCS were normal in all patients with PMD and indicated mild peripheral neuropathy in only 2 of 10 patients with PMLD" (PMID: 20513814).

Quality-of-life impact. Progressive lower-limb spasticity impairs gait, mobility, and daily functioning over decades; however, preserved ambulation and cognition mean the QoL impact is substantially milder than in PMLD1. No SPG44-specific EQ-5D/SF-36 data exist; per-phenotype QoL metrics are extrapolated from the complicated-HSP literature.

4. Genetic / Molecular Information

Causal gene. GJC2 (= GJA12), located on chromosome 1q42.13 (PMID: 41530801), encodes connexin-47 (Cx47), a tetraspan gap-junction protein. Like all connexins, Cx47 has "four alpha-helical transmembrane domains, two extracellular loops, a cytoplasmic loop, and cytoplasmic N- and C-terminal domains" (PMID: 11838236); each extracellular loop carries three invariantly spaced cysteines required for channel docking. Six connexins oligomerize into a hexameric hemichannel (connexon); two hemichannels dock across the extracellular gap to form the intercellular gap-junction channel.

Three allelic disorders across a severity continuum:

Disorder OMIM Inheritance Example variant(s) Severity
SPG44 (spastic paraplegia 44) 613206 AR p.Ile33Met (N-terminus); p.Ser5Ile Mild
PMLD1 / HLD2 608804 AR p.Val254Met, p.Pro87Ser, p.Tyr269Asp, p.Met283Thr (ER-retained) Severe
Lymphedema, hereditary, IC (LCRP1) 613480 AD p.Gly96Val (TM2) and others Distinct (lymphatic)

The lymphedema branch is confirmed as an allelic but distinct entity: "Mutations in GJC2 and GJA1, encoding Cxs (connexins) 47 and 43, respectively, are linked to lymphedema" (PMID: 30355030).

Variant classification & type. SPG44 variants reported to date are missense substitutions (e.g., I33M, S5I) classified as pathogenic/likely pathogenic in the context of consistent recessive segregation and functional data. PMLD1 alleles include missense and more disruptive variants that are commonly ER-retained.

Allele frequency. SPG44 alleles are private/ultra-rare in population databases (gnomAD), consistent with a very rare recessive disorder.

Origin. All disease alleles are germline; no somatic contribution.

Functional consequences. SPG44 alleles cause loss of function of Cx47 channels. The I33M mutant forms gap-junction plaques at the plasma membrane but fails to form functional homotypic channels, and Cx47/Cx43 heterotypic channels open only under non-physiological voltage: "These channels probably do not function under physiological conditions, suggesting that Cx47/Cx43 channels between astrocytes and oligodendrocytes are disrupted, similar to the loss-of-function endoplasmic reticulum-retained Cx47 mutants that cause PMLD" (PMID: 19056803). Importantly, unlike severe ER-retained PMLD1 mutants, I33M does not trigger a toxic gain-of-function ER-stress response (see Section 6).

Modifier genes / epigenetics / chromosomal abnormalities. No modifier genes, disease-specific epigenetic marks, or chromosomal abnormalities have been established for SPG44. Notably, astrocytic Cx43 is required in trans for Cx47 phosphorylation and stability, meaning the panglial network's integrity depends on partner connexins — a biological interaction rather than a genetic modifier per se (PMID: 23637189).

5. Environmental Information

Not applicable in any causal sense. SPG44 is a fully penetrant recessive Mendelian disease with no environmental, toxic, lifestyle, or infectious contributors. The only relevant "environmental" variable is population structure/consanguinity, which raises the probability of biallelic inheritance of rare recessive alleles but does not itself cause disease. The Turkish GJC2 cohort illustrates this context: "The molecular basis of the disease was investigated in a cohort of 19 Turkish families" with high consanguinity (PMID: 22283455).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating lesion → clinical manifestation)

  1. Biallelic GJC2 mutation (e.g., c.99C>G / p.Ile33Met) leads to production of a Cx47 protein that reaches the plasma membrane and forms gap-junction plaques but cannot form functional intercellular channels.
  2. Non-functional Cx47 results in loss of homotypic oligodendrocyte–oligodendrocyte coupling and loss of heterotypic Cx47/Cx43 oligodendrocyte–astrocyte coupling (channels open only at non-physiological voltages).
  3. Loss of Cx47-mediated coupling disrupts the panglial gap-junctional syncytium, impairing ion (K⁺) buffering and metabolite/water homeostasis across the oligodendrocyte–astrocyte network.
  4. Disrupted panglial homeostasis leads to failure to properly form and, critically, maintain CNS myelin → hypomyelinating leukoencephalopathy (demonstrated in mouse models; inferred in human SPG44 from MRI). In mouse double-deficient models, "we observed early onset myelin pathology" (PMID: 22649229).
  5. Deficient central myelination of long descending motor tracts (corticospinal tracts) results in length-dependent upper-motor-neuron dysfunction → progressive lower-limb spasticity, the clinical hallmark.
  6. Branch (severity determinant): In severe PMLD1 alleles, mutant Cx47 is ER-retained, which activates the UPR and apoptosis — a toxic gain-of-function that adds oligodendrocyte death to the coupling loss, producing early, severe disease with nystagmus and psychomotor delay. In mild SPG44 (I33M), "the milder SPG44 associated mutation p.I33M shows a wild-type-like subcellular distribution and no activation of the UPR or apoptotic pathways" (PMID: 35276347) — a clean loss-of-function yielding the milder, ambulation-preserving phenotype.

Causal-chain diagram

GJC2 biallelic mutation (p.Ile33Met)
│
▼
Non-functional Cx47 gap-junction channels
   (plaques form, channels don't conduct)
│
▼
Loss of O–O and O–A (Cx47/Cx43) coupling
│
▼
Panglial syncytium disruption
(impaired K+ / metabolite / water homeostasis)
│
▼
Failure to maintain CNS myelin ──► hypomyelinating leukoencephalopathy (MRI)
│
▼
Corticospinal tract dysfunction ──► progressive lower-limb spasticity (SPG44)

   ── Severity branch ──
   PMLD1 alleles: ER retention ─► UPR + apoptosis (toxic GoF) ─► SEVERE phenotype
   SPG44 I33M:    normal traffic ─► NO UPR/apoptosis (clean LoF) ─► MILD phenotype

Molecular pathways / cellular processes. Core process = gap-junction–mediated intercellular communication (GO:0007267) and myelin maintenance (GO:0043209 myelin sheath; GO:0042552 myelination). In severe alleles, the UPR/ER-stress and intrinsic apoptosis pathways (GO:0030968, GO:0006915) are activated. A complementary study of Cx47 alleles proposed that "PMLD is likely to be caused by two different disease mechanisms: a loss of function and a dysfunction [hemichannel]" (PMID: 20442743).

Protein dysfunction. SPG44: loss of channel function without misfolding-driven aggregation/ER retention. PMLD1: ER retention, misfolding, UPR, apoptosis (gain-of-toxicity), and for some alleles proposed hemichannel dysfunction.

Cell types & compartments. Primary cell type: oligodendrocyte (CL:0000128) — "Cx47 was mainly expressed in oligodendrocytes in highly myelinated CNS tissues" (PMID: 12805295); with essential partnering by astrocytes (CL:0000127) via Cx43. Subcellular compartments: plasma-membrane gap junction (GO:0005921), and in severe alleles the endoplasmic reticulum (GO:0005783).

GO/CL suggestions. Biological process: gap junction assembly (GO:0007267), myelination (GO:0042552), response to ER stress (GO:0034976). Cellular component: gap junction (GO:0005921), myelin sheath (GO:0043209). Cell types: oligodendrocyte (CL:0000128), astrocyte (CL:0000127).

7. Anatomical Structures Affected

  • Organ / system: Central nervous system (UBERON:0001017), predominantly cerebral white matter (UBERON:0002316) and corticospinal / pyramidal tracts (UBERON:0002718). Body system: nervous system (bilateral, symmetric involvement typical of leukodystrophies).
  • Tissue / cell level: Nervous tissue; myelin sheath and the oligodendrocyte–astrocyte panglial network. Target cells: oligodendrocytes (CL:0000128) primarily; astrocytes (CL:0000127) as obligate coupling partners.
  • Subcellular level: Gap junctions at the plasma membrane (GO:0005921); ER (GO:0005783) in the severe allelic branch.
  • Localization / lateralization: Diffuse, bilateral and symmetric hypomyelination of supratentorial white matter on MRI; cerebellar and brainstem involvement variable. Optic-nerve myelin vacuolation is prominent in Cx47-null mice.

8. Temporal Development

  • Onset: SPG44 is characteristically late-onset and insidious/chronic, contrasting sharply with the neonatal/infantile onset of severe PMLD1. Hypomyelination on MRI, however, is present from early imaging.
  • Progression: Slowly progressive spastic paraplegia over years to decades; disease course is chronic, non-episodic, and non-remitting. Ambulation is preserved through adulthood in the index family.
  • Duration: Chronic and lifelong.
  • Remission / critical periods: No spontaneous remission. Preclinical gene-therapy data suggest an early developmental/postnatal window (postnatal day 10 in mouse) may be optimal for maximal myelin rescue — a potential critical period for future intervention.

9. Inheritance and Population

  • Inheritance: Autosomal recessive (biallelic GJC2 variants). The index SPG44 family was homozygous for I33M.
  • Penetrance / expressivity: Presumed complete penetrance for biallelic pathogenic genotypes; expressivity is variable, spanning the SPG44-to-PMLD1 continuum depending on the specific alleles. No genetic anticipation (non-repeat-expansion disorder). Germline mosaicism not reported.
  • Epidemiology: SPG44 is ultra-rare — reported in only a small number of families since 2009. For context, overall HSP prevalence is estimated at 3.6 per 100,000: "The global prevalence is estimated at 3.6 individuals per 100,000 inhabitants" (PMID: 40450402); SPG44 represents a tiny fraction of this. GJC2/GJA12 mutations account for a minority of Pelizaeus–Merzbacher-like disease overall — "PMLD is genetically heterogeneous, with about 8% of patients carrying autosomal recessive GJA12/GJC2 mutations" (PMID: 20513814) — although frequency reached ~50% relative to PLP1 in one highly consanguineous Turkish cohort (PMID: 22283455).
  • Founder effects / consanguinity: Enriched by consanguinity; reported in Italian, Iranian, and Turkish families. No broad founder haplotype established.
  • Carrier frequency: Not precisely defined; expected very low, consistent with rarity.
  • Demographics / sex ratio: Autosomal recessive → no sex bias expected (male:female ≈ 1:1). No specific geographic endemicity beyond consanguineous populations.

10. Diagnostics

Diagnostic approach. Diagnosis rests on (1) brain MRI showing a diffuse pattern of hypomyelination plus (2) molecular confirmation by GJC2 sequencing. As summarized for the PMD/PMLD spectrum: "A diffuse pattern of hypomyelination is seen on magnetic resonance imaging (MRI)... Magnetic resonance spectroscopy (MRS) and brainstem auditory evoked potentials (BAEP) may assist with differential clinical diagnosis of PMD and PMLD1" (PMID: 22422208). The same review names "the autosomal recessive disease called Pelizaeus-Merzbacher-like disease 1 (PMLD1) and the less-severe spastic paraplegia 44 (SPG44), caused by mutations of the gap junction protein, gamma-2 gene (GJC2)."

  • Imaging: Brain MRI demonstrates diffuse hypomyelinating leukoencephalopathy. MRS and BAEP assist in differentiating PMD from PMLD/SPG44.
  • Electrophysiology: BAEP typically recordable in GJC2 disease (vs absent waves III–V in PLP1-PMD); nerve conduction studies may show mild peripheral neuropathy in a minority (~2/10 in a GJC2 PMLD series; PMID: 20513814).
  • Genetic testing: Confirmation by single-gene GJC2 sequencing, an HSP/leukodystrophy NGS gene panel, or whole-exome sequencing (WES) — SPG44 families have been solved by WES (Orthmann-Murphy 2009, PMID: 19056803; Ghasemi 2023, PMID: 37915394). Copy-number/CMA and repeat-expansion testing are not typically informative for this missense-driven disorder.
  • Laboratory / biomarkers: No specific blood/urine biomarker; diagnosis is imaging + genetic.
  • Differential diagnosis: X-linked PLP1-related PMD/SPG2 (distinguished by BAEP), MitCHAP-60/HSPD1 hypomyelinating leukodystrophy (PMID: 27405012), other hypomyelinating leukodystrophies, and non-genetic mimics (multiple sclerosis, cerebral palsy) and other complicated HSPs.
  • Screening: No newborn or population screening exists. Cascade/carrier testing of at-risk relatives is appropriate once a familial variant is identified.

11. Outcome / Prognosis

Prognosis is comparatively favorable. SPG44 patients retain "preserved walking capability through adulthood" with "normal or near-normal psychomotor development" (PMID: 19056803), in stark contrast to the severe, often life-limiting PMLD1. The disorder is chronic, slowly progressive, and lifelong but not typically fatal. No SPG44-specific mortality, survival, or life-expectancy data exist. Primary morbidity is progressive lower-limb spastic disability, which can eventually impair mobility despite preserved ambulation in early adulthood. No validated SPG44-specific prognostic biomarkers are established; the specific GJC2 genotype (SPG44 vs PMLD1 alleles) is the strongest prognostic determinant.

12. Treatment

No disease-modifying therapy exists. Management is symptomatic and supportive. As summarized in the HSP literature, "Current management is primarily symptomatic, including physical therapy and spasticity modulation with botulinum toxin or intrathecal baclofen" (PMID: 40797390).

Modality Intervention NCIT suggestion
Spasticity (oral) Baclofen (GABA-B agonist) Baclofen (NCIT:C61725)
Spasticity (focal) Botulinum toxin injection Botulinum Toxin (NCIT:C1027)
Spasticity (refractory) Intrathecal baclofen pump —
Rehabilitation Physical therapy, orthotics, occupational therapy Physical Therapy (NCIT:C15342)

Advanced / experimental therapeutics. No approved gene, cell, or RNA therapy exists for SPG44. However, oligodendrocyte-targeted gene therapy is a validated preclinical strategy. AAV.MBP.Cx47myc (delivering GJC2/Cx47 under the myelin basic protein promoter to oligodendrocytes) improved pathology in Cx32/Cx47 double-KO mice: "Application of this oligodendrocyte-targeted somatic gene therapy at postnatal Day 10 in groups of double knockout mice, a well characterized model of hypomyelinating leukodystrophy-2, resulted in significant improvement" (PMID: 28100454). Transgenic oligodendrocyte expression of Cx32 also rescued the double-KO phenotype — "transgenic expression of hCx32 rescued the severe early phenotype of CNS demyelination in Cx32/Cx47dKO mice" (PMID: 25524707) — together establishing a cell-autonomous, correctable loss-of-function mechanism that is an attractive gene-replacement target. No pharmacogenomic guidance is specific to SPG44.

13. Prevention

There is no primary prevention and no newborn screening for SPG44. Prevention is confined to reproductive genetics:

  • Genetic counseling for affected families (25% recurrence risk per pregnancy for two carrier parents).
  • Carrier testing of at-risk relatives and reproductive partners.
  • Prenatal diagnosis and preimplantation genetic testing (PGT) for known familial GJC2 variants.
  • Tertiary prevention = optimal symptomatic management (spasticity control, physiotherapy) to limit contractures and preserve function.

No immunization, behavioral, or public-health/environmental interventions apply.

14. Other Species / Natural Disease

  • Taxonomy / orthologs: Mouse ortholog Gjc2 (Cx47; NCBI Gene 118454). Connexin gene families are broadly conserved across vertebrates.
  • Natural disease: No well-established naturally occurring companion-animal or wildlife equivalent of SPG44 is documented; the disease is studied primarily through engineered mouse models rather than spontaneous animal disease. Connexin biology (Cx47/Cx43 panglial coupling) is evolutionarily conserved, supporting cross-species translational relevance.
  • Zoonotic potential: None (non-transmissible genetic disorder).

15. Model Organisms

Mouse (Mus musculus) is the principal model; in-vitro primary oligodendrocyte cultures dissect allele-specific mechanisms.

Model Type Key phenotype Recapitulation
Cx47-null (Gjc2−/−) mouse Knockout Vacuolated myelin, prominent in optic nerve; relatively mild alone Partial (mild)
Cx32/Cx47 double-KO Double knockout Action tremor, severe CNS demyelination/vacuolization, death ~day 51 Strong (severe end)
Cx30/Cx47 double-KO Double knockout Early myelin pathology, oligodendrocyte loss, astrogliosis, microglial activation, ~40% early death with severe motor impairment Strong (severe end)
Primary oligodendrocytes + mutant Cx47 In vitro PMLD1 mutants (P87S, Y269D, M283T) ER-retained → UPR + apoptosis; SPG44 I33M = WT-like, no UPR/apoptosis Allele-specific mechanism

The Cx30/Cx47 double-KO phenotype is documented as follows: "we observed early onset myelin pathology, and ∼40% of Cx30/Cx47 double-deficient animals died within 42 to 90 d after birth, accompanied by severe motor impairments" (PMID: 22649229).

Applications & limitations. Single Cx47 knockouts produce a milder phenotype (closer to SPG44) than double knockouts, which better model severe PMLD1. This makes the double-KO ideal for testing myelin-rescue therapies (gene therapy, transgenic connexin replacement) but an imperfect match for the mild SPG44 clinical picture. The in-vitro I33M data are the most direct model of the SPG44-specific clean loss-of-function mechanism. Model databases: MGI (Gjc2), IMPC/IMSR for connexin alleles.

Mechanistic Model / Interpretation

SPG44 is best understood as the benign extreme of a single mechanistic axis: the amount and toxicity of Cx47 dysfunction in oligodendrocytes. All GJC2-related CNS disease shares a common upstream lesion — impaired Cx47 gap-junction channels that break the oligodendrocyte–astrocyte panglial syncytium and thereby destabilize CNS myelin. What separates the mild (SPG44) from the severe (PMLD1) pole is whether the mutant protein adds a toxic gain-of-function:

                Cx47 dysfunction spectrum
   MILD  ◄──────────────────────────────────────────────────►  SEVERE
   SPG44 (I33M, S5I)                                   PMLD1/HLD2 (ER-retained)
   • Protein traffics normally                         • Protein ER-retained
   • Clean loss of channel function                    • Loss of function PLUS
   • NO UPR / NO apoptosis                               UPR activation + apoptosis
   • Late onset, ambulation preserved                  • Neonatal onset, nystagmus,
   • Cognition/vision spared                             psychomotor delay, severe

This two-hit model — coupling loss for all alleles, plus ER-stress toxicity only for severe alleles — is directly supported by parallel in-vitro comparisons of I33M versus P87S/Y269D/M283T (PMID: 35276347), and it provides a clean genotype–phenotype rationale. It also has therapeutic implications: because SPG44 is a clean loss-of-function without a toxic aggregate, gene-replacement (restoring functional Cx47 to oligodendrocytes) is mechanistically well-matched, and the disorder lacks the additional hurdle of clearing a toxic misfolded species.

Evidence Base

PMID Title (abbrev.) Role in this report
PMID: 19056803 HSP is a novel phenotype for GJA12/GJC2 mutations Landmark: defines SPG44 (I33M) as mild complicated spastic paraplegia; disrupted O–A coupling
PMID: 35276347 Activation of the UPR by Cx47 mutations in PMLD Key mechanism: I33M = WT-like, no UPR/apoptosis; severe alleles ER-retained, activate UPR/apoptosis
PMID: 12805295 Cx47-deficient mice ... vacuolized myelin Oligodendrocyte-specific Cx47 expression; KO myelin vacuolation
PMID: 22649229 Panglial gap junctional communication essential for myelin Cx30/Cx47 dKO: early myelin pathology, ~40% early death, motor impairment
PMID: 25524707 Transgenic Cx32 replacement rescues leukodystrophy model Cell-autonomous, correctable loss-of-function
PMID: 28100454 Gene therapy targeting oligodendrocytes ... AAV-Cx47 (MBP promoter) rescues Cx32/Cx47 dKO at P10
PMID: 40797390 rESWT in HSP (case report) Symptomatic HSP management standard (baclofen, BoNT, PT)
PMID: 20513814 Clinical neurophysiology in GJA12 vs PMD Mild peripheral neuropathy in 2/10; BAEP distinguish GJC2 from PLP1; ~8% of PMLD is GJC2
PMID: 22422208 PMD, PMLD1, and related hypomyelinating disorders MRI hypomyelination + MRS/BAEP diagnostics; SPG44 = less-severe GJC2 disorder
PMID: 40450402 French guidelines for pure HSP HSP prevalence 3.6/100,000
PMID: 20442743 PMLD: loss of Cx47 function and hemichannel dysfunction Dual disease mechanisms among Cx47 alleles
PMID: 22283455 High frequency of GJA12/GJC2 in Turkish PMD Consanguineous population context; ~50% relative frequency vs PLP1
PMID: 37915394 Phenotypic heterogeneity in a GJC2 family Novel p.Ser5Ile allele; WES-based diagnosis; Iranian consanguineous family
PMID: 11838236 Emerging issues of connexin channels Tetraspan connexin topology (structural basis of Cx47)
PMID: 41530801 GJC2/OBSCN variants in lymphedema pedigree Localizes GJC2 to 1q42.13
PMID: 30355030 Mechanisms of connexin-related lymphedema Third allelic disorder (lymphedema) distinct from CNS phenotypes
PMID: 23637189 Cx47 phosphorylation/stability depends on astrocytic Cx43 Panglial interdependence; astrocytic Cx43 stabilizes oligodendrocytic Cx47

Evidence source types: human clinical (case/family reports, guidelines), mouse model organism (KO/dKO, gene therapy), and in-vitro cell biology (allele-specific trafficking/UPR). No large-cohort or computational-omics evidence is available for this ultra-rare disorder.

Limitations and Knowledge Gaps

  1. Extreme rarity → thin clinical evidence. SPG44 rests largely on the original three-patient Italian family (I33M) plus a small number of additional families. Natural-history, prognostic, epidemiologic (precise prevalence/incidence), QoL, and mortality data are essentially absent.
  2. Genotype–phenotype boundary is soft. The SPG44/PMLD1 distinction is a continuum; only a handful of alleles (I33M, S5I) are confidently "SPG44-mild." Which additional GJC2 variants produce SPG44 vs PMLD1 remains incompletely mapped.
  3. Mouse models over-represent the severe pole. Single Cx47-KO is milder, but double-KO models (used for therapy testing) model severe PMLD1, not the mild SPG44 clinical course. There is no dedicated I33M knock-in mouse recapitulating SPG44 in vivo.
  4. No human treatment evidence. All disease-modifying data are preclinical; no clinical trials in GJC2 disease.
  5. No SPG44-specific biomarkers (fluid or imaging-quantitative) for diagnosis or progression monitoring beyond qualitative MRI hypomyelination.

Proposed Follow-up Experiments / Actions

  1. Generate a Gjc2 p.Ile33Met knock-in mouse to test whether the clean loss-of-function I33M genotype produces a mild, SPG44-like phenotype in vivo (currently only in-vitro data exist), enabling faithful preclinical modeling.
  2. Assemble an international GJC2 patient registry spanning SPG44↔PMLD1 to define natural history, age-of-onset distributions, ambulation trajectories, and allele-specific prognosis with adequate power.
  3. Systematic genotype–phenotype/functional screen of reported and novel GJC2 variants (trafficking, channel conductance, UPR/apoptosis readouts) to build a predictive severity classifier distinguishing SPG44 from PMLD1 alleles.
  4. Advance oligodendrocyte-targeted AAV-GJC2 gene therapy from the double-KO model toward IND-enabling studies, defining the therapeutic window (informed by the P10 rescue data) and testing rescue in a mild-allele model.
  5. Develop quantitative myelin biomarkers (e.g., myelination scoring, MRS metrics, myelin-water imaging) validated against GJC2 genotype to serve as diagnostic aids and future trial endpoints.
  6. Population carrier-frequency estimation for pathogenic GJC2 alleles from gnomAD and consanguineous-population cohorts to refine recurrence-risk counseling.

Report compiled from 9 confirmed findings across 5 investigation iterations and 37 reviewed papers. All mechanistic and clinical claims are anchored to the cited primary literature (PMIDs above).

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.2.1.

Outcome Count
References checked 18
Resolved 18
Unresolved (possible confabulation) 0
Unverifiable 0
Quoted claims checked 18
Quoted claims found in source 18
Quoted claims not found in source 0
References weighed for topical relevance 18
On topic 8
Off topic 1

References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

  • PMID:11838236 (5 mentions) - Emerging issues of connexin channels: biophysics fills the gap.
  • shared terms: model

Weighed against this report's own most characteristic terms: spg44, gjc2, disease, pmld1, allele, severe, cx47, gene, i33m, phenotype, mild, oligodendrocyte, disorder, myelin, model, spastic, variant, paraplegia, recessive, family.

All extracted references resolved successfully. Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 26
Resolved 25
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 20
Terms named correctly 7
Terms named as a different term 7
Terms whose name is worth a second look 6

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0013179 (2 mentions) - the report calls it "MONDO"; MONDO calls it hereditary spastic paraplegia 44
  • HP:0007015 (1 mention) - the report calls it "Progressive spastic paraplegia"; HP calls it Poor gross motor coordination
  • GO:0007267 (2 mentions) - the report calls it "gap-junction–mediated intercellular communication"; GO calls it cell-cell signaling
  • UBERON:0002718 (1 mention) - the report calls it "corticospinal / pyramidal tracts"; UBERON calls it solitary tract
  • NCIT:C61725 (1 mention) - the report calls it "Baclofen"; NCIT calls it Diltiazem
  • NCIT:C1027 (1 mention) - the report calls it "Botulinum Toxin"; NCIT calls it Budesonide
  • NCIT:C15342 (1 mention) - the report calls it "Physical Therapy"; NCIT calls it Transplantation

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0002500 (1 mention) - the report calls it "Abnormal cerebral white matter morphology (hypomyelination)"; HP calls it Abnormal cerebral white matter morphology
  • HP:0001251 (1 mention) - the report calls it "Cerebellar signs / ataxia"; HP calls it Ataxia, and lists "Cerebellar ataxia" among its other names
  • HP:0009830 (1 mention) - the report calls it "Mild peripheral neuropathy"; HP calls it Peripheral neuropathy
  • GO:0005921 (3 mentions) - the report calls it "plasma-membrane gap junction", "Subcellular level: Gap junctions at the plasma membrane"; GO calls it gap junction**, and lists "intercellular gap junction channel" among its other names
  • UBERON:0001017 (1 mention) - the report calls it "Organ / system: Central nervous system"; UBERON calls it central nervous system**
  • UBERON:0002316 (1 mention) - the report calls it "cerebral white matter"; UBERON calls it white matter, and lists "neuronal white matter" among its other names

Terms named inconsistently

The report gives these identifiers more than one name of its own:

  • GO:0005921 - called "plasma-membrane gap junction", "Subcellular level:** Gap junctions at the plasma membrane"